WHAT IS CLAIMED:

1. A compound of Formula (I):



(I)

or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein;

W is -NH- or -O-;

Q is selected from $-(CR^{10}R^{10c})_n-Q^1$, $-(CR^{10}R^{10c})_n-Q^2$,
C_1-C_4 alkyl substituted with Q^1,
C_2-C_4 alkenyl substituted with Q^1,
C_2-C_4 alkynyl substituted with Q^1, and
an amino acid residue;

Q^1 is selected from
$-CO_2R^{11}$, $-SO_2R^{11}$, $-SO_3R^{11}$, $-P(O)_2R^{11}$, $-P(O)_3R^{11}$,
aryl substituted with 0-4 Q^{1a}, and
5-6 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N, said heterocyclic group substituted with 0-4 Q^{1a};

Q^{1a} is H, F, Cl, Br, I, $-NO_2$, -CN, -NCS, $-CF_3$, $-OCF_3$, $-CH_3$, $-OCH_3$, $-CO_2R^{19}$, $-C(=O)NR^{19}R^{19}$, $-NHC(=O)R^{19}$, $-SO_2R^{19}$, $-SO_2NR^{19}R^{19}$, $-NR^{19}R^{19}$, $-OR^{19}$, $-SR^{19}$, C_1-C_4 alkyl, C_1-C_4 alkoxy, C_1-C_4 haloalkyl, or C_1-C_4 haloalkoxy;

R^{19} is C_1-C_4 alkyl, C_1-C_4 haloalkyl, aryl, aryl(C_1-C_4 alkyl), C_3-C_6 cycloalkyl, or C_3-C_6 cycloalkyl(C_1-C_4 alkyl);

alternatively, $NR^{19}R^{19}$ may form a 5-6 membered heterocyclic group consisting of carbon atoms, a nitrogen atom, and optionally a second heteroatom selected from the group: O, S, and N;

R^{10} is selected from the group: $-CO_2R^{11}$, $-NR^{11}R^{11}$, and C_1-C_6 alkyl substituted with 0-1 R^{10a};

R^{10a} is selected from the group: halo, $-NO_2$, $-CN$, $-CF_3$, $-CO_2R^{11}$, $-NR^{11}R^{11}$, $-OR^{11}$, $-SR^{11}$, $-C(=NH)NH_2$, and aryl substituted with 0-1 R^{10b};

R^{10b} is selected from the group: $-CO_2H$, $-NH_2$, $-OH$, $-SH$, and $-C(=NH)NH_2$;

R^{10c} is H or C_1-C_4 alkyl;

alternatively, R^{10} and R^{10c} can be combined to form a C_3-C_6 cycloalkyl group substituted with 0-1 R^{10a};

R^{11} is, at each occurrence, independently H or C_1-C_4 alkyl;

R^{11a} is H, C_1-C_4 alkyl, C_1-C_4 haloalkyl, C_2-C_4 alkenyl, C_2-C_4 alkynyl, aryl, aryl(C_1-C_4 alkyl)-, C_3-C_6 cycloalkyl, or C_3-C_6 cycloalkyl(C_1-C_4 alkyl)-;

Q^2 is $-X-NR^{12}-Z$, $-NR^{12}-Y-Z$, or $-X-NR^{12}-Y-Z$;

X is selected from the group: $-C(=O)-$, $-S-$, $-S(=O)-$, $-S(=O)_2-$, $-P(O)-$, $-P(O)_2-$, and $-P(O)_3-$;

Y is selected from the group: $-C(=O)-$, $-S-$, $-S(=O)-$, $-S(=O)_2-$, $-P(O)-$, $-P(O)_2-$, and $-P(O)_3-$;

R^{12} is H or C_1-C_4 alkyl;

Z is C_1-C_4 haloalkyl,
C_1-C_4 alkyl substituted with 0-3 Z^a,
C_2-C_4 alkenyl substituted with 0-3 Z^a,
C_2-C_4 alkynyl substituted with 0-3 Z^a,
C_3-C_{10} cycloalkyl substituted with 0-5 Z^b,
C_3-C_{10} carbocyle substituted with 0-5 Z^b,
aryl substituted with 0-5 Z^b,
5-10 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N, said heterocyclic group substituted with 0-4 Z^b;
an amino acid residue, or
$-A^7-A^8-A^9$;

Z^a is H, F, Cl, Br, I, $-NO_2$, -CN, -NCS, $-CF_3$, $-OCF_3$, $-CH_3$, $-OCH_3$, $-CO_2R^{20}$, $-C(=O)NR^{20}R^{20}$, $-NHC(=O)R^{20}$, $-NR^{20}R^{20}$,
$-OR^{20}$, $-SR^{20}$, $-S(=O)R^{20}$, $-SO_2R^{20}$, $-SO_2NR^{20}R^{20}$,
C_1-C_4 alkyl, C_1-C_4 alkoxy, C_1-C_4 haloalkyl,
C_1-C_4 haloalkoxy,

C_3-C_{10} cycloalkyl substituted with 0-5 Z^b,
C_3-C_{10} carbocyle substituted with 0-5 Z^b,
aryl substituted with 0-5 Z^b, or
5-10 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N, said heterocyclic group substituted with 0-4 Z^b;

Z^b is H, F, Cl, Br, I, $-NO_2$, -CN, -NCS, $-CF_3$, $-OCF_3$, $-CH_3$, $-OCH_3$, $-CO_2R^{20}$, $-C(=O)NR^{20}R^{20}$, $-NHC(=O)R^{20}$, $-NR^{20}R^{20}$,
$-OR^{20}$, $-SR^{20}$, $-S(=O)R^{20}$, $-SO_2R^{20}$, $-SO_2NR^{20}R^{20}$,

C_1-C_4 alkyl, C_1-C_4 alkoxy, C_1-C_4 haloalkyl, C_1-C_4 haloalkoxy,

C_3-C_{10} cycloalkyl substituted with 0-5 Z^c,
C_3-C_{10} carbocyle substituted with 0-5 Z^c,
aryl substituted with 0-5 Z^c, or
5-10 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N, said heterocyclic group substituted with 0-4 Z^c;

Z^c is H, F, Cl, Br, I, $-NO_2$, -CN, -NCS, $-CF_3$, $-OCF_3$, $-CH_3$, $-OCH_3$, $-CO_2R^{20}$, $-C(=O)NR^{20}R^{20}$, $-NHC(=O)R^{20}$, $-NR^{20}R^{20}$,
$-OR^{20}$, $-SR^{20}$, $-S(=O)R^{20}$, $-SO_2R^{20}$, $-SO_2NR^{20}R^{20}$,
C_1-C_4 alkyl, C_1-C_4 alkoxy, C_1-C_4 haloalkyl, or C_1-C_4 haloalkoxy;

R^{20} is H, C_1-C_4 alkyl, C_1-C_4 haloalkyl, aryl, aryl(C_1-C_4 alkyl)-, C_3-C_6 cycloalkyl, or C_3-C_6 cycloalkyl(C_1-C_4 alkyl)-;

alternatively, $NR^{20}R^{20}$ may form a 5-6 membered heterocyclic group consisting of carbon atoms, a nitrogen atom, and optionally a second heteroatom selected from the group: O, S, and N;

A^2 is a bond, $-NH-CR^3R^4-C(=O)-$, an amino acid residue,



or


;

A^3 is a bond, $-NH-CR^5R^6-C(=O)-$, or an amino acid residue;

A^4 is a bond, $-NH-CR^7R^8-C(=O)-$, or an amino acid residue;

A^5 is a bond or an amino acid residue;

A^6 is a bond or an amino acid residue;

A^7 is a bond or an amino acid residue;

A^8 is an amino acid residue;

A^9 is an amino acid residue;

R^1 is selected from the group: H, F,
C_1-C_6 alkyl substituted with 0-3 R^{1a},
C_2-C_6 alkenyl substituted with 0-3 R^{1a},
C_2-C_6 alkynyl substituted with 0-3 R^{1a},
aryl substituted with 0-5 R^{1a}, and
C_3-C_6 cycloalkyl substituted with 0-3 R^{1a};

R^{1a} is selected at each occurrence from the group:
Cl, F, Br, I, CF_3, CHF_2, OH, =O, SH, $-CO_2R^{1b}$, $-SO_2R^{1b}$,
$-SO_3R^{1b}$, $-P(O)_2R^{1b}$, $-P(O)_3R^{1b}$, $-C(=O)NHR^{1b}$, $-NHC(=O)R^{1b}$,
$-SO_2NHR^{1b}$, $-OR^{1b}$, $-SR^{1b}$, C_1-C_3 alkyl, C_3-C_6 cycloalkyl,
C_1-C_6 alkoxy, -S-(C_1-C_6 alkyl),
aryl substituted with 0-5 R^{1c},
$-O-(CH_2)_q$-aryl substituted with 0-5 R^{1c},
$-S-(CH_2)_q$-aryl substituted with 0-5 R^{1c}, and
5-10 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N, and substituted with 0-3 R^{1c};

R^{1b} is H,
C_1-C_4 alkyl substituted with 0-3 R^{1c},
C_2-C_4 alkenyl substituted with 0-3 R^{1c},
C_2-C_4 alkynyl substituted with 0-3 R^{1c},
C_3-C_6 cycloalkyl substituted with 0-5 R^{1c},

C_3-C_6 carbocyle substituted with 0-5 R^{1c},
aryl substituted with 0-5 R^{1c}, or
5-6 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N, said heterocyclic group substituted with 0-4 R^{1c};

R^{1c} is selected at each occurrence from: C_1-C_4 alkyl, Cl, F, Br, I, OH, C_1-C_4 alkoxy, -CN, $-NO_2$, $C(O)OR^{1d}$, $NR^{1d}R^{1d}$, CF_3, and OCF_3;

R^{1d} is H or C_1-C_4 alkyl;

R^2 is H, F, or C_1-C_4 alkyl;

R^3 is selected from the group: H,
C_1-C_6 alkyl substituted with 0-4 R^{3a},
C_2-C_6 alkenyl substituted with 0-4 R^{3a},
C_2-C_6 alkynyl substituted with 0-4 R^{3a},
$-(CH_2)_q$- C_3-C_6 cycloalkyl substituted with 0-4 R^{3b},
$-(CH_2)_q$-aryl substituted with 0-5 R^{3b}, and
$-(CH_2)_q$-5-10 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N, and said heterocyclic group is substituted with 0-2 R^{3b};

R^{3a} is selected from the group: $-CO_2R^{11}$, $-NR^{11}R^{11}$, $-OR^{11}$, $-SR^{11}$, $-C(=NH)NH_2$, and aryl substituted with R^{10b};

R^{3b} is selected from the group: $-CO_2H$, $-NH_2$, -OH, -SH, and $-C(=NH)NH_2$;

R^{3c} is, at each occurrence, independently selected from: H, C_1-C_6 alkyl, -OH, and OR^{3d};

R^{3d} is C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, $-(CH_2)_q$- C_3-C_6 cycloalkyl, $-(CH_2)_q$-aryl, or $-(CH_2)_q$-(5-10 membered heterocyclic group), wherein said heterocyclic group consists of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N;

R^4 is selected from the group: H, C_1-C_6 alkyl, phenyl, phenylmethyl-, phenylethyl-, C_3-C_6 cycloalkyl, C_3-C_6 cycloalkylmethyl-, and C_3-C_6 cycloalkylethyl-;

R^5 and R^7 are independently H or R^3;

R^6 and R^8 are independently H or R^4;

R^9 is selected from the group: $-S(=O)R^{9a}$, $-S(=O)_2R^{9a}$, $-C(=O)R^{9a}$, $-C(=O)OR^{9a}$, $-C(=O)NHR^{9a}$, C_1-C_3 alkyl-R^{9a}, C_2-C_6 alkenyl-R^{9a}, and C_2-C_6 alkynyl-R^{9a};

R^{9a} is selected from the group:
C_1-C_6 alkyl substituted with 0-3 R^{9b},
C_3-C_6 cycloalkyl substituted with 0-3 R^{9c},
aryl substituted with 0-3 R^{9c}, and
5-14 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N, and said heterocyclic group is substituted with 0-3 R^{9c};

R^{9b} is selected from the group: phenyl, naphthyl, benzyl, and 5-10 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N, and R^{9b} is substituted with 0-3 R^{9c};

R^{9c} is selected at each occurrence from the group:

CF_3, OCF_3, Cl, F, Br, I, =O, OH, phenyl, $C(O)OR^{11}$, NH_2, $NH(CH_3)$, $N(CH_3)_2$, -CN, NO_2;

C_1-C_4 alkyl substituted with 0-3 R^{9d},

C_1-C_4 alkoxy substituted with 0-3 R^{9d},

C_3-C_6 cycloalkyl substituted with 0-3 R^{9d},

aryl substituted with 0-5 R^{9d}, and

5-6 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N, and said heterocyclic group is substituted with 0-4 R^{9d};

R^{9d} is selected at each occurrence from the group: C_1-C_4 alkyl, C_1-C_4 alkoxy, CF_3, OCF_3, Cl, F, Br, I, =O, OH, phenyl, $C(O)OR^{11}$, NH_2, $NH(CH_3)$, $N(CH_3)_2$, -CN, and NO_2;

an amino acid residue, at each occurence, independently comprises a natural amino acid, a modified amino acid or an unnatural amino acid wherein said natural, modified or unnatural amino acid is of either D or L configuration;

n is 1, 2, 3, or 4; and

p is 1 or 2; and

q, at each occurence, is independently 0, 1 or 2.

2. A compound according to Claim 1, wherein

Q is $-(CR^{10}R^{10c})_n-Q^2$ or an amino acid residue, wherein the amino acid residue comprises a natural, a modified or an unnatural amino acid.

3. A compound according to Claim 2, wherein the compound is of Formula (II):



(II)

or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein;

R^{10} is selected from the group: $-CO_2R^{11}$, $-NR^{11}R^{11}$, and C_1-C_6 alkyl substituted with 0-1 R^{10a};

R^{10a} is selected from the group: halo, $-NO_2$, $-CN$, $-CF_3$, $-CO_2R^{11}$, $-NR^{11}R^{11}$, $-OR^{11}$, $-SR^{11}$, $-C(=NH)NH_2$, and aryl substituted with 0-1 R^{10b};

R^{10b} is selected from the group: $-CO_2H$, $-NH_2$, $-OH$, $-SH$, and $-C(=NH)NH_2$;

R^{10c} is H or C_1-C_4 alkyl;

alternatively, R^{10} and R^{10c} can be combined to form a C_3-C_6 cycloalkyl group substituted with 0-1 R^{10a};

R^{11} is, at each occurrence, independently H or C_1-C_4 alkyl;

R^{11a} is H, C_1-C_4 alkyl, C_1-C_4 haloalkyl, C_2-C_4 alkenyl, C_2-C_4 alkynyl, aryl, aryl(C_1-C_4 alkyl)-, C_3-C_6 cycloalkyl, or C_3-C_6 cycloalkyl(C_1-C_4 alkyl)-;

Q^2 is $-X-NR^{12}-Z$, $-NR^{12}-Y-Z$, or $-X-NR^{12}-Y-Z$;

X is selected from the group: $-C(=O)-$, $-S-$, $-S(=O)-$, $-S(=O)_2-$, $-P(O)-$, $-P(O)_2-$, and $-P(O)_3-$;

Y is selected from the group: $-C(=O)-$, $-S-$, $-S(=O)-$, $-S(=O)_2-$, $-P(O)-$, $-P(O)_2-$, and $-P(O)_3-$;

R^{12} is H or C_1-C_4 alkyl;

Z is C_1-C_4 haloalkyl,
C_1-C_4 alkyl substituted with 0-3 Z^a,
C_2-C_4 alkenyl substituted with 0-3 Z^a,
C_2-C_4 alkynyl substituted with 0-3 Z^a,
C_3-C_{10} cycloalkyl substituted with 0-5 Z^b,
C_3-C_{10} carbocyle substituted with 0-5 Z^b,
aryl substituted with 0-5 Z^b,
5-10 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N, said heterocyclic group substituted with 0-4 Z^b;
an amino acid residue, or
$-A^7-A^8-A^9$;

Z^a is H, F, Cl, Br, I, $-NO_2$, $-CN$, $-NCS$, $-CF_3$, $-OCF_3$, $-CH_3$, $-OCH_3$, $-CO_2R^{20}$, $-C(=O)NR^{20}R^{20}$, $-NHC(=O)R^{20}$, $-NR^{20}R^{20}$,
$-OR^{20}$, $-SR^{20}$, $-S(=O)R^{20}$, $-SO_2R^{20}$, $-SO_2NR^{20}R^{20}$,
C_1-C_4 alkyl, C_1-C_4 alkoxy, C_1-C_4 haloalkyl,
C_1-C_4 haloalkoxy,
C_3-C_{10} cycloalkyl substituted with 0-5 Z^b,
C_3-C_{10} carbocyle substituted with 0-5 Z^b,
aryl substituted with 0-5 Z^b, or
5-10 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N, said heterocyclic group substituted with 0-4 Z^b;

Z^b is H, F, Cl, Br, I, $-NO_2$, -CN, -NCS, $-CF_3$, $-OCF_3$, $-CH_3$, $-OCH_3$, $-CO_2R^{20}$, $-C(=O)NR^{20}R^{20}$, $-NHC(=O)R^{20}$, $-NR^{20}R^{20}$,
$-OR^{20}$, $-SR^{20}$, $-S(=O)R^{20}$, $-SO_2R^{20}$, $-SO_2NR^{20}R^{20}$,
C_1-C_4 alkyl, C_1-C_4 alkoxy, C_1-C_4 haloalkyl,
C_1-C_4 haloalkoxy,

C_3-C_{10} cycloalkyl substituted with 0-5 Z^c,
C_3-C_{10} carbocyle substituted with 0-5 Z^c,
aryl substituted with 0-5 Z^c, or
5-10 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N, said heterocyclic group substituted with 0-4 Z^c;

Z^c is H, F, Cl, Br, I, $-NO_2$, -CN, -NCS, $-CF_3$, $-OCF_3$, $-CH_3$, $-OCH_3$, $-CO_2R^{20}$, $-C(=O)NR^{20}R^{20}$, $-NHC(=O)R^{20}$, $-NR^{20}R^{20}$,
$-OR^{20}$, $-SR^{20}$, $-S(=O)R^{20}$, $-SO_2R^{20}$, $-SO_2NR^{20}R^{20}$,
C_1-C_4 alkyl, C_1-C_4 alkoxy, C_1-C_4 haloalkyl, or C_1-C_4 haloalkoxy;

R^{20} is H, C_1-C_4 alkyl, C_1-C_4 haloalkyl, aryl, aryl(C_1-C_4 alkyl)-, C_3-C_6 cycloalkyl, or C_3-C_6 cycloalkyl(C_1-C_4 alkyl)-;

alternatively, $NR^{20}R^{20}$ may form a 5-6 membered heterocyclic group consisting of carbon atoms, a nitrogen atom, and optionally a second heteroatom selected from the group: O, S, and N;

A^2 is a bond, $-NH-CR^3R^4-C(=O)-$, an amino acid residue,



or

;

A^3 is a bond, $-NH-CR^5R^6-C(=O)-$, or an amino acid residue;

A^4 is a bond, $-NH-CR^7R^8-C(=O)-$, or an amino acid residue;

A^5 is a bond or an amino acid residue;

A^7 is a bond or an amino acid residue;

A^8 is an amino acid residue;

A^9 is an amino acid residue;

R^1 is selected from the group: H, F,
C_1-C_6 alkyl substituted with 0-3 R^{1a},
C_2-C_6 alkenyl substituted with 0-3 R^{1a},
C_2-C_6 alkynyl substituted with 0-3 R^{1a}, and
C_3-C_6 cycloalkyl substituted with 0-3 R^{1a};

R^{1a} is selected at each occurrence from the group:
Cl, F, Br, I, CF_3, CHF_2, OH, =O, SH,
$-CO_2R^{1b}$, $-SO_2R^{1b}$, $-SO_3R^{1b}$, $-P(O)_2R^{1b}$, $-P(O)_3R^{1b}$,
$-C(=O)NHR^{1b}$, $-NHC(=O)R^{1b}$, $-SO_2NHR^{1b}$, $-OR^{1b}$, $-SR^{1b}$,
C_1-C_3 alkyl, C_3-C_6 cycloalkyl, C_1-C_6 alkoxy,
$-S-(C_1$-C_6 alkyl),
aryl substituted with 0-5 R^{1c},
$-O-(CH_2)_q$-aryl substituted with 0-5 R^{1c},
$-S-(CH_2)_q$-aryl substituted with 0-5 R^{1c}, and
5-10 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N, and substituted with 0-3 R^{1c};

R^{1b} is H,
C_1-C_4 alkyl substituted with 0-3 R^{1c},
C_2-C_4 alkenyl substituted with 0-3 R^{1c},
C_2-C_4 alkynyl substituted with 0-3 R^{1c},
C_3-C_6 cycloalkyl substituted with 0-5 R^{1c},
C_3-C_6 carbocyle substituted with 0-5 R^{1c},
aryl substituted with 0-5 R^{1c}, or
5-6 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N, said heterocyclic group substituted with 0-4 R^{1c};

R^{1c} is selected at each occurrence from: C_1-C_4 alkyl, Cl, F, Br, I, OH, C_1-C_4 alkoxy, -CN, $-NO_2$, $C(O)OR^{1d}$, $NR^{1d}R^{1d}$, CF_3, and OCF_3;

R^{1d} is H or C_1-C_4 alkyl;

R^2 is H, F, or C_1-C_4 alkyl;

R^3 is selected from the group: H,
C_1-C_6 alkyl substituted with 0-4 R^{3a},
C_2-C_6 alkenyl substituted with 0-4 R^{3a},
C_2-C_6 alkynyl substituted with 0-4 R^{3a},
$-(CH_2)_q$- C_3-C_6 cycloalkyl substituted with 0-4 R^{3b},
$-(CH_2)_q$-aryl substituted with 0-5 R^{3b}, and
$-(CH_2)_q$-5-10 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N, and said heterocyclic group is substituted with 0-2 R^{3b};

R^{3a} is selected from the group: $-CO_2R^{11}$, $-NR^{11}R^{11}$, $-OR^{11}$, $-SR^{11}$, $-C(=NH)NH_2$, and aryl substituted with R^{10b};

R^{3b} is selected from the group: $-CO_2H$, $-NH_2$, -OH, -SH, and $-C(=NH)NH_2$;

R^{3c} is, at each occurrence, independently selected from: H, C_1-C_6 alkyl, -OH, and OR^{3d};

R^{3d} is C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, $-(CH_2)_q$- C_3-C_6 cycloalkyl, $-(CH_2)_q$-aryl, or $-(CH_2)_q$-(5-10 membered heterocyclic group), wherein said heterocyclic group consists of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N;

R^4 is selected from the group: H, C_1-C_6 alkyl, phenyl, phenylmethyl-, phenylethyl-, C_3-C_6 cycloalkyl, C_3-C_6 cycloalkylmethyl-, and C_3-C_6 cycloalkylethyl-;

R^5 and R^7 are independently H or R^3;

R^6 and R^8 are independently H or R^4;

R^9 is selected from the group: $-S(=O)R^{9a}$, $-S(=O)_2R^{9a}$, $-C(=O)R^{9a}$, $-C(=O)OR^{9a}$, $-C(=O)NHR^{9a}$, C_1-C_3 alkyl-R^{9a}, C_2-C_6 alkenyl-R^{9a}, and C_2-C_6 alkynyl-R^{9a};

R^{9a} is selected from the group:
C_1-C_6 alkyl substituted with 0-3 R^{9b},
C_3-C_6 cycloalkyl substituted with 0-3 R^{9c},
aryl substituted with 0-3 R^{9c}, and
5-14 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N, and said heterocyclic group is substituted with 0-3 R^{9c};

R^{9b} is selected from the group: phenyl, naphthyl, benzyl, and 5-10 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N, and R^{9b} is substituted with 0-3 R^{9c};

R^{9c} is selected at each occurrence from the group:
CF_3, OCF_3, Cl, F, Br, I, =O, OH, phenyl, $C(O)OR^{11}$, NH_2, $NH(CH_3)$, $N(CH_3)_2$, -CN, NO_2;
C_1-C_4 alkyl substituted with 0-3 R^{9d},
C_1-C_4 alkoxy substituted with 0-3 R^{9d},
C_3-C_6 cycloalkyl substituted with 0-3 R^{9d},
aryl substituted with 0-5 R^{9d}, and
5-6 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N, and said heterocyclic group is substituted with 0-4 R^{9d};

R^{9d} is selected at each occurrence from the group:
C_1-C_4 alkyl, C_1-C_4 alkoxy, CF_3, OCF_3, Cl, F, Br, I, =O, OH, phenyl, $C(O)OR^{11}$, NH_2, $NH(CH_3)$, $N(CH_3)_2$, -CN, and NO_2;

n is 1, 2, or 3; and

p is 1 or 2; and

q, at each occurence, is independently 0, 1 or 2.

4. A compound according to Claim 3, wherein

R^{10} is selected from the group: $-CO_2R^{11}$, $-NR^{11}R^{11}$, and C_1-C_6 alkyl substituted with 0-1 R^{10a};

R^{10a} is selected from the group: halo, $-NO_2$, -CN, $-CF_3$,

$-CO_2R^{11}$, $-NR^{11}R^{11}$, $-OR^{11}$, $-SR^{11}$, $-C(=NH)NH_2$, and aryl substituted with 0-1 R^{10b};

R^{10b} is selected from the group: $-CO_2H$, $-NH_2$, $-OH$, $-SH$, and $-C(=NH)NH_2$;

R^{10c} is H or C_1-C_4 alkyl;

alternatively, R^{10} and R^{10c} can be combined to form a C_3-C_6 cycloalkyl group substituted with 0-1 R^{10a};

R^{11} is, at each occurrence, independently H or C_1-C_4 alkyl;

R^{11a} is H, C_1-C_4 alkyl, C_1-C_4 haloalkyl, C_2-C_4 alkenyl, C_2-C_4 alkynyl, aryl, aryl(C_1-C_4 alkyl)-, C_3-C_6 cycloalkyl, or C_3-C_6 cycloalkyl(C_1-C_4 alkyl)-;

Q^2 is $-X-NR^{12}-Z$, $-NR^{12}-Y-Z$, or $-X-NR^{12}-Y-Z$;

X is selected from the group: $-C(=O)-$, $-S-$, $-S(=O)-$, and $-S(=O)_2-$;

Y is selected from the group: $-C(=O)-$, $-S-$, $-S(=O)-$, and $-S(=O)_2-$;

R^{12} is H or C_1-C_4 alkyl;

Z is C_1-C_4 haloalkyl,
C_1-C_4 alkyl substituted with 0-3 Z^a,
C_2-C_4 alkenyl substituted with 0-3 Z^a,
C_2-C_4 alkynyl substituted with 0-3 Z^a,
C_3-C_{10} cycloalkyl substituted with 0-5 Z^b,
C_3-C_{10} carbocyle substituted with 0-5 Z^b,
aryl substituted with 0-5 Z^b,

5-10 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N, said heterocyclic group substituted with 0-4 Z^b;

an amino acid residue, or

$-A^7-A^8-A^9$;

Z^a is H, F, Cl, Br, I, $-NO_2$, -CN, -NCS, $-CF_3$, $-OCF_3$, $-CH_3$, $-OCH_3$, $-CO_2R^{20}$, $-C(=O)NR^{20}R^{20}$, $-NHC(=O)R^{20}$, $-NR^{20}R^{20}$,

$-OR^{20}$, $-SR^{20}$, $-S(=O)R^{20}$, $-SO_2R^{20}$, $-SO_2NR^{20}R^{20}$,

C_1-C_4 alkyl, C_1-C_4 alkoxy, C_1-C_4 haloalkyl, C_1-C_4 haloalkoxy,

C_3-C_{10} cycloalkyl substituted with 0-5 Z^b,

C_3-C_{10} carbocyle substituted with 0-5 Z^b,

aryl substituted with 0-5 Z^b, or

5-10 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N, said heterocyclic group substituted with 0-4 Z^b;

Z^b is H, F, Cl, Br, I, $-NO_2$, -CN, -NCS, $-CF_3$, $-OCF_3$, $-CH_3$, $-OCH_3$, $-CO_2R^{20}$, $-C(=O)NR^{20}R^{20}$, $-NHC(=O)R^{20}$, $-NR^{20}R^{20}$,

$-OR^{20}$, $-SR^{20}$, $-S(=O)R^{20}$, $-SO_2R^{20}$, $-SO_2NR^{20}R^{20}$,

C_1-C_4 alkyl, C_1-C_4 alkoxy, C_1-C_4 haloalkyl, C_1-C_4 haloalkoxy,

C_3-C_{10} cycloalkyl substituted with 0-5 Z^c,

C_3-C_{10} carbocyle substituted with 0-5 Z^c,

aryl substituted with 0-5 Z^c, or

5-10 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group:

O, S, and N, said heterocyclic group substituted with 0-4 Z^c;

Z^c is H, F, Cl, Br, I, $-NO_2$, -CN, -NCS, $-CF_3$, $-OCF_3$, $-CH_3$, $-OCH_3$, $-CO_2R^{20}$, $-C(=O)NR^{20}R^{20}$, $-NHC(=O)R^{20}$, $-NR^{20}R^{20}$, $-OR^{20}$, $-SR^{20}$, $-S(=O)R^{20}$, $-SO_2R^{20}$, $-SO_2NR^{20}R^{20}$, C_1-C_4 alkyl, C_1-C_4 alkoxy, C_1-C_4 haloalkyl, or C_1-C_4 haloalkoxy;

R^{20} is H, C_1-C_4 alkyl, C_1-C_4 haloalkyl, aryl, aryl(C_1-C_4 alkyl)-, C_3-C_6 cycloalkyl, or C_3-C_6 cycloalkyl(C_1-C_4 alkyl)-;

alternatively, $NR^{20}R^{20}$ may form a piperidinyl, piperazinyl, or morpholinyl group;

A^2 is a bond, $-NH-CR^3R^4-C(=O)-$, an amino acid residue,



or


;

A^3 is a bond or an amino acid residue;

A^4 is a bond or an amino acid residue;

A^5 is a bond;

R^1 is selected from the group: H,
C_1-C_6 alkyl substituted with 0-3 R^{1a},
C_2-C_6 alkenyl substituted with 0-3 R^{1a},
C_2-C_6 alkynyl substituted with 0-3 R^{1a}, and
C_3-C_6 cycloalkyl substituted with 0-3 R^{1a};

R^{1a} is selected at each occurrence from the group:
Cl, F, Br, I, CF_3, CHF_2, OH, =O, SH, $-CO_2R^{1b}$, $-SO_2R^{1b}$, $-SO_3R^{1b}$, $-P(O)_2R^{1b}$, $-P(O)_3R^{1b}$, $-C(=O)NHR^{1b}$, $-NHC(=O)R^{1b}$, $-SO_2NHR^{1b}$, $-OR^{1b}$, $-SR^{1b}$, C_1-C_3 alkyl, C_3-C_6 cycloalkyl, C_1-C_6 alkoxy, $-S-(C_1$-C_6 alkyl),
aryl substituted with 0-5 R^{1c},
$-O-(CH_2)_q$-aryl substituted with 0-5 R^{1c},
$-S-(CH_2)_q$-aryl substituted with 0-5 R^{1c}, and
5-10 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N, and substituted with 0-3 R^{1c};

R^{1b} is H,
C_1-C_4 alkyl substituted with 0-3 R^{1c},
C_2-C_4 alkenyl substituted with 0-3 R^{1c},
C_2-C_4 alkynyl substituted with 0-3 R^{1c},
C_3-C_6 cycloalkyl substituted with 0-5 R^{1c},
C_3-C_6 carbocyle substituted with 0-5 R^{1c},
aryl substituted with 0-5 R^{1c}, or
5-6 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N, said heterocyclic group substituted with 0-4 R^{1c};

R^{1c} is selected at each occurrence from: C_1-C_4 alkyl, Cl, F, Br, I, OH, C_1-C_4 alkoxy, -CN, $-NO_2$, $C(O)OR^{1d}$, $NR^{1d}R^{1d}$, CF_3, and OCF_3;

R^{1d} is H or C_1-C_4 alkyl;

R^2 is H or C_1-C_4 alkyl;

R^3 is selected from the group: H,
C_1-C_6 alkyl substituted with 0-4 R^{3a},

C_2-C_6 alkenyl substituted with 0-4 R^{3a},
C_2-C_6 alkynyl substituted with 0-4 R^{3a},
$-(CH_2)_q$- C_3-C_6 cycloalkyl substituted with 0-4 R^{3b},
$-(CH_2)_q$-aryl substituted with 0-5 R^{3b}, and
$-(CH_2)_q$-5-10 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N, and said heterocyclic group is substituted with 0-2 R^{3b};

R^{3a} is selected from the group: $-CO_2R^{11}$, $-NR^{11}R^{11}$, $-OR^{11}$, $-SR^{11}$, $-C(=NH)NH_2$, and aryl substituted with R^{10b};

R^{3b} is selected from the group: $-CO_2H$, $-NH_2$, -OH, -SH, and $-C(=NH)NH_2$;

R^{3c} is, at each occurrence, independently selected from: H, C_1-C_6 alkyl, -OH, and OR^{3d};

R^{3d} is C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, $-(CH_2)_q$- C_3-C_6 cycloalkyl, $-(CH_2)_q$-aryl, or $-(CH_2)_q$-(5-10 membered heterocyclic group), wherein said heterocyclic group consists of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N;

R^4 is selected from the group: H, C_1-C_6 alkyl, phenyl, phenylmethyl-, phenylethyl-, C_3-C_6 cycloalkyl, C_3-C_6 cycloalkylmethyl-, and C_3-C_6 cycloalkylethyl-;

R^9 is selected from the group: $-S(=O)_2R^{9a}$, $-C(=O)R^{9a}$, C_1-C_3 alkyl-R^{9a}, C_2-C_6 alkenyl-R^{9a}, and C_2-C_6 alkynyl-R^{9a};

R^{9a} is selected from the group:
C_1-C_6 alkyl substituted with 0-3 R^{9b},

C_3-C_6 cycloalkyl substituted with 0-3 R^{9c},
aryl substituted with 0-3 R^{9c}, and
5-14 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N, and said heterocyclic group is substituted with 0-3 R^{9c};

R^{9b} is selected from the group: phenyl, naphthyl, benzyl, and 5-10 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N, and R^{9b} is substituted with 0-3 R^{9c};

R^{9c} is selected at each occurrence from the group:
CF_3, OCF_3, Cl, F, Br, I, =O, OH, phenyl, $C(O)OR^{11}$, NH_2, $NH(CH_3)$, $N(CH_3)_2$, -CN, NO_2;
C_1-C_4 alkyl substituted with 0-3 R^{9d},
C_1-C_4 alkoxy substituted with 0-3 R^{9d},
C_3-C_6 cycloalkyl substituted with 0-3 R^{9d},
aryl substituted with 0-5 R^{9d}, and
5-6 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N, and said heterocyclic group is substituted with 0-4 R^{9d};

R^{9d} is selected at each occurrence from the group:
C_1-C_4 alkyl, C_1-C_4 alkoxy, CF_3, OCF_3, Cl, F, Br, I, =O, OH, phenyl, $C(O)OR^{11}$, NH_2, $NH(CH_3)$, $N(CH_3)_2$, -CN, and NO_2;

n is 1 or 2; and

p is 1 or 2; and

q, at each occurence, is independently 0, 1 or 2.

5. A compound according to Claim 4, wherein the compound is of Formula (III):



(III)

or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein;

R^{11} is, at each occurrence, independently H or C_1-C_4 alkyl;

X is -C(=O)-, -S-, -S(=O)-, or -$S(=O)_2$-;

Y is -C(=O)- or -$S(=O)_2$-;

Z is C_1-C_4 haloalkyl,
C_1-C_4 alkyl substituted with 0-3 Z^a,
C_2-C_4 alkenyl substituted with 0-3 Z^a,
C_2-C_4 alkynyl substituted with 0-3 Z^a,
C_3-C_{10} cycloalkyl substituted with 0-5 Z^b,
C_3-C_{10} carbocyle substituted with 0-5 Z^b,
aryl substituted with 0-5 Z^b, or
5-10 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: pyridinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, pyrazinyl, piperazinyl, piperidinyl, imidazolyl, imidazolidinyl, indolyl, tetrazolyl, isoxazolyl, morpholinyl, oxazolyl, oxazolidinyl, tetrahydrofuranyl, thiadiazinyl, thiadiazolyl, thiazolyl, triazinyl, triazolyl, benzimidazolyl, 1*H*-indazolyl, benzofuranyl, benzothiofuranyl, benztetrazolyl, benzotriazolyl, benzisoxazolyl, benzoxazolyl, oxindolyl, benzoxazolinyl, benzthiazolyl, benzisothiazolyl, isatinoyl, isoquinolinyl, octahydroisoquinolinyl,

tetrahydroisoquinolinyl, tetrahydroquinolinyl, isoxazolopyridinyl, quinazolinyl, quinolinyl, isothiazolopyridinyl, thiazolopyridinyl, oxazolopyridinyl, imidazolopyridinyl, and pyrazolopyridinyl; said heterocyclic group substituted with 0-4 Z^b;

Z^a is H, F, Cl, Br, I, $-NO_2$, -CN, -NCS, $-CF_3$, $-OCF_3$, $-CH_3$, $-OCH_3$, $-CO_2R^{20}$, $-C(=O)NR^{20}R^{20}$, $-NHC(=O)R^{20}$, $-NR^{20}R^{20}$,
$-OR^{20}$, $-SR^{20}$, $-S(=O)R^{20}$, $-SO_2R^{20}$, $-SO_2NR^{20}R^{20}$,
C_1-C_4 alkyl, C_1-C_4 alkoxy, C_1-C_4 haloalkyl,
C_1-C_4 haloalkoxy,

C_3-C_{10} cycloalkyl substituted with 0-5 Z^b,
C_3-C_{10} carbocyle substituted with 0-5 Z^b,
aryl substituted with 0-5 Z^b, or
5-10 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: pyridinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, pyrazinyl, piperazinyl, piperidinyl, imidazolyl, imidazolidinyl, indolyl, tetrazolyl, isoxazolyl, morpholinyl, oxazolyl, oxazolidinyl, tetrahydrofuranyl, thiadiazinyl, thiadiazolyl, thiazolyl, triazinyl, triazolyl, benzimidazolyl, 1*H*-indazolyl, benzofuranyl, benzothiofuranyl, benztetrazolyl, benzotriazolyl, benzisoxazolyl, benzoxazolyl, oxindolyl, benzoxazolinyl, benzthiazolyl, benzisothiazolyl, isatinoyl, isoquinolinyl, octahydroisoquinolinyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, isoxazolopyridinyl, quinazolinyl, quinolinyl, isothiazolopyridinyl, thiazolopyridinyl, oxazolopyridinyl, imidazolopyridinyl, and pyrazolopyridinyl; said heterocyclic group substituted with 0-4 Z^b;

Z^b is H, F, Cl, Br, I, $-NO_2$, -CN, -NCS, $-CF_3$, $-OCF_3$, $-CH_3$, $-OCH_3$, $-CO_2R^{20}$, $-C(=O)NR^{20}R^{20}$, $-NHC(=O)R^{20}$, $-NR^{20}R^{20}$,
$-OR^{20}$, $-SR^{20}$, $-S(=O)R^{20}$, $-SO_2R^{20}$, $-SO_2NR^{20}R^{20}$,
C_1-C_4 alkyl, C_1-C_4 alkoxy, C_1-C_4 haloalkyl,
C_1-C_4 haloalkoxy,

C_3-C_{10} cycloalkyl substituted with 0-5 Z^c,
C_3-C_{10} carbocyle substituted with 0-5 Z^c,
aryl substituted with 0-5 Z^c, or
5-10 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: pyridinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, pyrazinyl, piperazinyl, piperidinyl, imidazolyl, imidazolidinyl, indolyl, tetrazolyl, isoxazolyl, morpholinyl, oxazolyl, oxazolidinyl, tetrahydrofuranyl, thiadiazinyl, thiadiazolyl, thiazolyl, triazinyl, triazolyl, benzimidazolyl, 1*H*-indazolyl, benzofuranyl, benzothiofuranyl, benztetrazolyl, benzotriazolyl, benzisoxazolyl, benzoxazolyl, oxindolyl, benzoxazolinyl, benzthiazolyl, benzisothiazolyl, isatinoyl, isoquinolinyl, octahydroisoquinolinyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, isoxazolopyridinyl, quinazolinyl, quinolinyl, isothiazolopyridinyl, thiazolopyridinyl, oxazolopyridinyl, imidazolopyridinyl, and pyrazolopyridinyl; said heterocyclic group substituted with 0-4 Z^c;

Z^c is H, F, Cl, Br, I, $-NO_2$, -CN, -NCS, $-CF_3$, $-OCF_3$, $-CH_3$, $-OCH_3$, $-CO_2R^{20}$, $-C(=O)NR^{20}R^{20}$, $-NHC(=O)R^{20}$, $-NR^{20}R^{20}$,
$-OR^{20}$, $-SR^{20}$, $-S(=O)R^{20}$, $-SO_2R^{20}$, $-SO_2NR^{20}R^{20}$,

C_1-C_4 alkyl, C_1-C_4 alkoxy, C_1-C_4 haloalkyl, or C_1-C_4 haloalkoxy;

R^{20} is H, C_1-C_4 alkyl, C_1-C_4 haloalkyl, aryl, aryl(C_1-C_4 alkyl)-, C_3-C_6 cycloalkyl, or C_3-C_6 cycloalkyl(C_1-C_4 alkyl)-;

alternatively, $NR^{20}R^{20}$ may form a piperidinyl, piperazinyl, or morpholinyl group;

A^2 is a bond, -NH-CR^3R^4-C(=O)-, Ala, Arg, Asn, Asp, Aze, Cha, Cys, Dpa, Gln, Glu, Gly, His, Hyp, Ile, Irg, Leu, Lys, Met, Orn, Phe, Phe(4-fluoro), Pro, Sar, Ser, Thr, Trp, Tyr, Val,



or


;

A^3 is a bond, Ala, Arg, Asn, Asp, Aze, Cha, Cys, Dpa, Gln, Glu, Gly, His, Hyp, Ile, Irg, Leu, Lys, Met, Orn, Phe, Phe(4-fluoro), Pro, Sar, Ser, Thr, Trp, Tyr, or Val;

A^4 is a bond, Ala, Arg, Asn, Asp, Aze, Cha, Cys, Dpa, Gln, Glu, Gly, His, Hyp, Ile, Irg, Leu, Lys, Met, Orn, Phe, Phe(4-fluoro), Pro, Sar, Ser, Thr, Trp, Tyr, or Val;

R^1 is selected from the group: H,
C_1-C_6 alkyl substituted with 0-3 R^{1a},
C_2-C_6 alkenyl substituted with 0-3 R^{1a},
C_2-C_6 alkynyl substituted with 0-3 R^{1a}, and
C_3-C_6 cycloalkyl substituted with 0-3 R^{1a};

R^{1a} is selected at each occurrence from the group:
Cl, F, Br, I, CF_3, CHF_2, OH, =O, SH, $-CO_2R^{1b}$, $-SO_2R^{1b}$,

$-SO_3R^{1b}$, $-P(O)_2R^{1b}$, $-P(O)_3R^{1b}$, $-C(=O)NHR^{1b}$, $-NHC(=O)R^{1b}$, $-SO_2NHR^{1b}$, $-OR^{1b}$, $-SR^{1b}$, C_1-C_3 alkyl, C_3-C_6 cycloalkyl, C_1-C_6 alkoxy, -S-(C_1-C_6 alkyl),
aryl substituted with 0-5 R^{1c},
$-O-(CH_2)_q$-aryl substituted with 0-5 R^{1c},
$-S-(CH_2)_q$-aryl substituted with 0-5 R^{1c}, and
5-10 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: pyridinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, pyrazinyl, piperazinyl, piperidinyl, imidazolyl, imidazolidinyl, indolyl, tetrazolyl, isoxazolyl, morpholinyl, oxazolyl, oxazolidinyl, tetrahydrofuranyl, thiadiazinyl, thiadiazolyl, thiazolyl, triazinyl, triazolyl, benzimidazolyl, 1*H*-indazolyl, benzofuranyl, benzothiofuranyl, benztetrazolyl, benzotriazolyl, benzisoxazolyl, benzoxazolyl, oxindolyl, benzoxazolinyl, benzthiazolyl, benzisothiazolyl, isatinoyl, isoquinolinyl, octahydroisoquinolinyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, isoxazolopyridinyl, quinazolinyl, quinolinyl, isothiazolopyridinyl, thiazolopyridinyl, oxazolopyridinyl, imidazolopyridinyl, and pyrazolopyridinyl; and substituted with 0-3 R^{1c};

R^{1b} is H,
C_1-C_4 alkyl substituted with 0-3 R^{1c},
C_2-C_4 alkenyl substituted with 0-3 R^{1c},
C_2-C_4 alkynyl substituted with 0-3 R^{1c},
C_3-C_6 cycloalkyl substituted with 0-5 R^{1c},
C_3-C_6 carbocyle substituted with 0-5 R^{1c},
aryl substituted with 0-5 R^{1c}, or
5-6 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: pyridinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, pyrazinyl, piperazinyl, piperidinyl, imidazolyl,

imidazolidinyl, indolyl, tetrazolyl, isoxazolyl, morpholinyl, oxazolyl, oxazolidinyl, tetrahydrofuranyl, thiadiazinyl, thiadiazolyl, thiazolyl, triazinyl, and triazolyl; said heterocyclic group substituted with 0-3 R^{1c};

R^{1c} is selected at each occurrence from: C_1-C_4 alkyl, Cl, F, Br, I, OH, C_1-C_4 alkoxy, -CN, $-NO_2$, $C(O)OR^{1d}$, $NR^{1d}R^{1d}$, CF_3, and OCF_3;

R^{1d} is H or C_1-C_4 alkyl;

R^2 is H or C_1-C_4 alkyl;

R^3 is selected from the group: H,
C_1-C_6 alkyl substituted with 0-4 R^{3a},
C_2-C_6 alkenyl substituted with 0-4 R^{3a},
C_2-C_6 alkynyl substituted with 0-4 R^{3a},
$-(CH_2)_q$- C_3-C_6 cycloalkyl substituted with 0-4 R^{3b},
$-(CH_2)_q$-aryl substituted with 0-5 R^{3b}, and
$-(CH_2)_q$-5-10 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: pyridinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, pyrazinyl, piperazinyl, piperidinyl, imidazolyl, imidazolidinyl, indolyl, tetrazolyl, isoxazolyl, morpholinyl, oxazolyl, oxazolidinyl, tetrahydrofuranyl, thiadiazinyl, thiadiazolyl, thiazolyl, triazinyl, triazolyl, benzimidazolyl, 1*H*-indazolyl, benzofuranyl, benzothiofuranyl, benztetrazolyl, benzotriazolyl, benzisoxazolyl, benzoxazolyl, oxindolyl, benzoxazolinyl, benzthiazolyl, benzisothiazolyl, isatinoyl, isoquinolinyl, octahydroisoquinolinyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, isoxazolopyridinyl, quinazolinyl, quinolinyl, isothiazolopyridinyl, thiazolopyridinyl,

oxazolopyridinyl, imidazolopyridinyl, and pyrazolopyridinyl; and said heterocyclic group is substituted with 0-2 R^{3b};

R^{3a} is selected from the group: $-CO_2R^{11}$, $-NR^{11}R^{11}$, $-OR^{11}$, $-SR^{11}$, $-C(=NH)NH_2$, and aryl substituted with R^{10b};

R^{3b} is selected from the group: $-CO_2H$, $-NH_2$, -OH, -SH, and $-C(=NH)NH_2$;

R^{3c} is, at each occurrence, independently selected from: H, C_1-C_6 alkyl, -OH, and OR^{3d};

R^{3d} is C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, $-(CH_2)_q$- C_3-C_6 cycloalkyl, $-(CH_2)_q$-aryl, or $-(CH_2)_q$-(5-10 membered heterocyclic group), wherein said heterocyclic group consists of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N;

R^4 is selected from the group: H, C_1-C_6 alkyl, phenyl, phenylmethyl-, phenylethyl-, C_3-C_6 cycloalkyl, C_3-C_6 cycloalkylmethyl-, and C_3-C_6 cycloalkylethyl-;

R^9 is selected from $-S(=O)_2R^{9a}$ and $-C(=O)R^{9a}$;

R^{9a} is selected from the group:
phenyl substituted with 0-3 R^{9c},
naphthyl substituted with 0-3 R^{9c}, and
5-14 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: pyridinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, pyrazinyl, piperazinyl, piperidinyl, imidazolyl, imidazolidinyl, indolyl, tetrazolyl, isoxazolyl, morpholinyl, oxazolyl, oxazolidinyl, tetrahydrofuranyl, thiadiazinyl, thiadiazolyl,

thiazolyl, triazinyl, triazolyl, benzimidazolyl, 1*H*-indazolyl, benzofuranyl, benzothiofuranyl, benztetrazolyl, benzotriazolyl, benzisoxazolyl, benzoxazolyl, oxindolyl, benzoxazolinyl, benzthiazolyl, benzisothiazolyl, isatinoyl, isoquinolinyl, octahydroisoquinolinyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, isoxazolopyridinyl, quinazolinyl, quinolinyl, isothiazolopyridinyl, thiazolopyridinyl, oxazolopyridinyl, imidazolopyridinyl, and pyrazolopyridinyl; and said heterocyclic group is substituted with 0-3 R^{9c};

R^{9c} is selected at each occurrence from the group:
CF_3, OCF_3, Cl, F, Br, I, =O, OH, phenyl, $C(O)OR^{11}$, NH_2, $NH(CH_3)$, $N(CH_3)_2$, -CN, NO_2;
C_1-C_4 alkyl substituted with 0-3 R^{9d},
C_1-C_4 alkoxy substituted with 0-3 R^{9d},
C_3-C_6 cycloalkyl substituted with 0-3 R^{9d},
aryl substituted with 0-5 R^{9d}, and
5-6 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: pyridinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, pyrazinyl, piperazinyl, piperidinyl, imidazolyl, imidazolidinyl, indolyl, tetrazolyl, isoxazolyl, morpholinyl, oxazolyl, oxazolidinyl, tetrahydrofuranyl, thiadiazinyl, thiadiazolyl, thiazolyl, triazinyl, and triazolyl; said heterocyclic group is substituted with 0-4 R^{9d};

R^{9d} is selected at each occurrence from the group:
C_1-C_4 alkyl, C_1-C_4 alkoxy, CF_3, OCF_3, Cl, F, Br, I, =O, OH, phenyl, $C(O)OR^{11}$, NH_2, $NH(CH_3)$, $N(CH_3)_2$, -CN, and NO_2;

p is 1 or 2; and

q, at each occurence, is independently 0, 1 or 2.

6. A compound of Claim 5, wherein

X is -C(=O)-;

Y is $-S(=O)_2-$;

Z is selected from the group:
methyl, ethyl, propyl, trifluoromethyl,
phenyl, benzyl, 4-phenyl-phenyl, 4-NCS-phenyl,
2-fluorophenyl-, 3-fluorophenyl-, 4-fluorophenyl-,
2-chlorophenyl-, 3-chlorophenyl-, 4-chlorophenyl-,
2-cyanophenyl-, 3-cyanophenyl-, 4-cyanophenyl-,
2-nitrophenyl-, 3-nitrophenyl-, 4-nitrophenyl-,
$2\text{-}CF_3SO_2\text{-phenyl-}$, $3\text{-}CF_3SO_2\text{-phenyl-}$, $4\text{-}CF_3SO_2\text{-phenyl-}$,
$2\text{-}CF_3\text{-phenyl-}$, $3\text{-}CF_3\text{-phenyl-}$, $4\text{-}CF_3\text{-phenyl-}$,
$3\text{-}NO_2\text{-}4\text{-Cl-phenyl-}$, $3\text{-Cl-}4\text{-}CH_3\text{-phenyl-}$,
$2\text{-Cl-}5\text{-}CF_3\text{-phenyl-}$, $2\text{-Cl-}5\text{-}CO_2H\text{-phenyl-}$,
$3\text{-}NO_2\text{-}4\text{-}CH_3\text{-phenyl-}$, $3\text{-Cl-}5\text{-}NH_2SO_2\text{-phenyl-}$,
$3,5\text{-di}CF_3\text{-phenyl-}$, $3,4\text{-di}CF_3\text{-phenyl-}$,
3,5-diCl-phenyl-, 2,5-diCl-phenyl-, 3,4-diCl-phenyl-,
3,5-diF-phenyl-, 2,5-diF-phenyl-, 3,4-diF-phenyl-,
$2\text{-F-}4\text{-Cl-}5\text{-}CO_2H\text{-phenyl-}$, $2,4\text{-diCl-}5\text{-}CO_2H\text{-phenyl-}$,
$2,4\text{-diCl-}5\text{-}CH_3CO_2\text{-phenyl-}$, $2,4\text{-diCl-}5\text{-}CH_3\text{-phenyl-}$,
2-OH-3,5-diCl-phenyl-, 2,4,5-triCl-phenyl-,
$3,5\text{-diCl-}4\text{-(4-}NO_2\text{phenyl)phenyl-}$,
$2\text{-Cl-}5\text{-benzylNHCO-phenyl-}$, $2\text{-Cl-}5\text{-}CF_3CH_2NHCO\text{-phenyl-}$,
2-Cl-5-cyclopropylmethylNHCO-phenyl-,
$2\text{-Cl-}4\text{-}CH_3CONH\text{-phenyl-}$, $3\text{-Cl-}5\text{-(phenylCONH}SO_2\text{)-phenyl-}$,
$3\text{-Cl-}5\text{-}CH_3CONH\text{-phenyl-}$, 5-ethoxy-benzothiazol-2-yl,
naphth-2-yl, (CH_3CONH)thiadiazolyl-,
(s-butylCONH)thiadiazolyl-, (n-pentylCONH)thiadiazolyl-,
(phenylCONH)thiadiazolyl-, and
(3-ClphenylCONH)thiadiazolyl-,

A^2 is a bond, Ala, Arg, Asn, Asp, Aze, Cha, Cys, Dpa, Gln, Glu, Gly, His, Hyp, Ile, Irg, Leu, Lys, Met, Orn, Phe, Phe(4-fluoro), Pro, Sar, Ser, Thr, Trp, Tyr, Val;



or


;

A^3 is a bond, Ala, Arg, Asn, Asp, Aze, Cha, Cys, Dpa, Gln, Glu, Gly, His, Hyp, Ile, Irg, Leu, Lys, Met, Orn, Phe, Phe(4-fluoro), Pro, Sar, Ser, Thr, Trp, Tyr, or Val;

A^3 is a bond, Ala, Arg, Asn, Asp, Aze, Cha, Cys, Dpa, Gln, Glu, Gly, His, Hyp, Ile, Irg, Leu, Lys, Met, Orn, Phe, Phe(4-fluoro), Pro, Sar, Ser, Thr, Trp, Tyr, or Val;

R^1 is selected from the group:

$-CH_2CH_3$, $-CH_2CH_2CH_3$, $-CH(CH_3)_2$, $-CH_2CH_2CH_2CH_3$, $-CH_2CH(CH_3)_2$, $-CH_2C(CH_3)_3$, $-CH_2CH_2C(CH_3)_3$, $-CH_2CH_2CH_2C(CH_3)_3$, $-CH_2CH_2CH_2CH(CH_3)_2$, $-CH_2CH_2CH_2CH(CH_2CH_3)_2$, $-CH_2CH_2CH_2CH_2CH_3$, $-CH_2CH_2CH(CH_3)_2$, $-CH_2CH_2CH_2CH_2CH_2CH_3$, $-CH_2CF_3$, $-CH_2CH_2CF_3$, $-CH_2CH_2CH_2CF_3$, $-CH_2CHF_2$, $-CH_2CH_2CHF_2$, $-CH_2CH_2CH_2CHF_2$, $-CH=CH_2$, $-CH_2CH=CH_2$, $-CH=CHCH_3$, cis-$CH_2CH=CH(CH_3)$, trans-$CH_2CH=CH(CH_3)$, $-CH_2CH_2CH=CH$, $-CH_2CH=C(CH_3)_2$, $-CH_2CH_2CH=C(CH_3)_2$, $-CH_2CO_2H$, $-CH_2CH_2CO_2H$, $-CH_2CO_2C(CH_3)_3$, $-CH_2CH_2CO_2C(CH_3)_3$, $-CH_2CH_2CH_2CH_2NH_2$, phenyl, benzyl, phenethyl, phenpropyl, phenbutyl, (2-methylphenyl)ethyl-, (3-methylphenyl)ethyl-, (4-methylphenyl)ethyl-, (4-ethylphenyl)ethyl-, (4-i-propylphenyl)ethyl-, (4-t-butylphenyl)ethyl-, (4-hydroxyphenyl)ethyl-, (4-phenyl-phenyl)ethyl-, (4-phenoxy-phenyl)ethyl-, (4-cyclohexyl-phenyl)ethyl-, (4-cyclopropyl-phenyl)ethyl-,

(2,5-dimethylphenyl)ethyl-,
(2,4-dimethylphenyl)ethyl-, (2,6-difluorophenyl)ethyl-,
(4-cyclopentyl-phenyl)ethyl-,
(4-cyclobutyl-phenyl)ethyl-,
(2-trifluoromethylphenyl)ethyl-,
(3-trifluoromethylphenyl)ethyl-,
(4-trifluoromethylphenyl)ethyl-,
(2-fluorophenyl)ethyl-, (3-fluorophenyl)ethyl-,
(4-fluorophenyl)ethyl-, (2-chlorophenyl)ethyl-,
(3-chlorophenyl)ethyl-, (4-chlorophenyl)ethyl-,
(2-bromophenyl)ethyl-, (3-bromophenyl)ethyl-,
(4-bromophenyl)ethyl-,
(2,3,4,5,6-pentafluorophenyl)ethyl-
(naphth-2-yl)ethyl, (cyclobutyl)methyl,
(cyclobutyl)ethyl, (cyclobutyl)propyl, cyclopropyl,
cyclobutyl, cyclopentyl, and cyclohexyl;

R^2 is H, methyl, or ethyl;

R^{3c} is H, methyl, ethyl, -OH, methoxy, ethoxy, propoxy,
phenoxy, or benzyloxy; and

R^9 is selected from:
2-pyrazinyl-carbonyl-,
4-(N-pyrrolyl)phenyl-carbonyl-,
5-(4-chlorophenyl)furan-2-yl-carbonyl-,
1-anthracenyl-carbonyl-,
7-nitro-anthracen-1-yl-carbonyl-,
(3-phenyl-2-cyanomethoxyphenyl)carbonyl-,
5-(2-Cl-3-CF_3-phenyl)-furan-2-yl-carbonyl-,
5-(4-Cl-phenyl)-furan-2-yl-carbonyl-,
5-(pyrid-2-yl)-thiophen-2-yl-carbonyl-,
(2-methoxyphenyl)ethylcarbonyl-,
(3-benzopyrrolyl)ethylcarbonyl-,
(N-phenyl-5-propyl-imidazol-4-yl)-carbonyl-,
1-naphthyl-sulphonyl-, and
5-(isoxazol-2-yl)thiophen-2-yl-sulphonyl-.

7. A compound according to Claim 1, wherein the compound is selected from the group:

N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-3-cyclohexyl-L-alanyl-2-oxo-(3S)-3-amino pentanoylglycine;

(3S)-2-oxo-3-{[N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-3-cyclohexyl-L-alanyl]amino}-N-(2H-tetrazol-5-ylmethyl) pentanamide;

2-oxo-3-[[N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-3-cyclohexylalanyl]amino]-N-(sulfomethyl)pentanamide;

N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-3-cyclohexylalanyl-2-oxo-3-aminopentanoyl-N-[(2-nitrophenyl) sulfonyl]glycinamide;

N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-3-cyclohexylalanyl-2-oxo-3-aminopentanoyl- N-(methylsulfonyl) glycinamide;

N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-3-cyclohexylalanyl-2-oxo-3-aminopentanoyl-N-[(phenylmethyl) sulfonyl]glycinamide;

N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-3-cyclohexylalanyl-2-oxo-3-aminopentanoyl- N-(phenylsulfonyl) glycinamide;

N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-3-cyclohexylalanyl-2-oxo-3-aminopentanoyl- N-[(trifluoromethyl)sulfonyl]glycinamide;

N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-3-cyclohexylalanyl-2-oxo-3-aminopentanoyl- N-[(2-nitrophenyl)sulfonyl]glycinamide;

N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-3-cyclohexylalanyl-2-oxo-3-aminopentanoyl- N-[(4-nitrophenyl)sulfonyl]glycinamide;

N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-3-cyclohexylalanyl-2-oxo-3-aminopentanoyl- N-[(4-fluorophenyl)sulfonyl]glycinamide;

N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-3-cyclohexyl-L-alanyl-2-oxo-(3 S)-3-amino pentanoyl-N-[(3-fluorophenyl)sulfonyl]glycinamide;

N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-3-cyclohexylalanyl-2-oxo-3-aminopentanoyl- N-[(2-fluorophenyl) sulfonyl]glycinamide;

N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-3-cyclohexylalanyl-2-oxo-3-aminopentanoyl- N-[(4-chlorophenyl) sulfonyl]glycinamide;

N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-3-cyclohexylalanyl-2-oxo-3-aminopentano yl-N-[(3-chlorophenyl) sulfonyl]glycinamide;

N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-3-cyclohexylalanyl-2-oxo-3-aminopentanoyl- N-[[4-(thionitroso) phenyl]sulfonyl]glycinamide;

N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-3-cyclohexylalanyl-2-oxo-3-aminopentanoyl- N-[[4-[(trifluoromethyl)sulfonyl]phenyl]sulfonyl]glycinamide;

N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-3-cyclohexylalanyl-2-oxo-3-aminopentanoyl- N-[[4-(trifluoromethyl)phenyl]sulfonyl]glycinamide;

N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-3-cyclohexylalanyl-2-oxo-3-aminopentanoyl- N-[(4-cyanophenyl)sulfonyl]glycinamide;

N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-3-cyclohexylalanyl-2-oxo-3-aminopentanoyl- N-[(3-chloro-4-methylphenyl)sulfonyl]glycinamide;

N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-3-cyclohexylalanyl-2-oxo-3-aminopentanoyl- N-[(4-chloro-3-nitrophenyl)sulfonyl]glycinamide;

N-(2-pyrazinylcarbonyl)-L-leucyl-L- isoleucyl-3-cyclohexylalanyl-2-oxo-3-aminopentanoyl- N-[(3,5-dichlorophenyl)sulfonyl]glycinamide;

N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-3-cyclohexylalanyl-2-oxo-3-aminopentanoyl- N-[(4-methyl-3-nitrophenyl)sulfonyl]glycinamide;

N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-3-cyclohexylalanyl-2-oxo-3-aminopentanoyl- N-[[2-chloro-5-(trifluoromethyl)phenyl]sulfonyl]glycinamide;

N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-3-cyclohexylalanyl-2-oxo-3-aminopentanoyl- N-[(5-carboxy-2-chlorophenyl)sulfonyl]glycinamide;

N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-3-cyclohexylalanyl-2-oxo-3-aminopentanoyl- N-[(2,5-dichlorophenyl)sulfonyl]glycinamide;

N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-3-cyclohexylalanyl-2-oxo-3-aminopentanoyl- N-[(3,4-difluorophenyl)sulfonyl]glycinamide;

N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-3-cyclohexylalanyl-2-oxo-3-aminopentanoyl- N-[(3,5-dichloro-2-hydroxyphenyl)sulfonyl]glycinamide;

N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-3-cyclohexyl-L-alanyl-2-oxo-(3S)-3-amino pentanoyl-N-[(2,4;,5-trichlorophenyl)-sulfonyl]glycinamide;

N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-3-cyclohexylalanyl-2-oxo-3-aminopentanoyl-N-[(5-carboxy-4-chloro-2-fluorophenyl)sulfonyl]glycinamide;

N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-3-cyclohexylalanyl-2-oxo-3-aminopentanoyl- N-[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]glycinamide;

N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-3-cyclohexylalanyl-2-oxo-3-aminopentanoyl- N-(2-naphthalenylsulfonyl)glycinamide;

N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-3-cyclohexyl-L- alanyl-2-oxo-(3S)-3-aminopentanoyl-N-[(4-(phenyl)phenyl)-sulfonyl]glycinamide;

N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-3-cyclohexylalanyl-2-oxo-3-aminopentanoyl- N-[(6-ethoxy-2-benzothiazolyl)sulfonyl]glycinamide;

N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-3-cyclohexylalanyl-2-oxo-3-aminopentanoyl- N-[[2-chloro-5-[[(phenylmethyl)amino]carbonyl]phenyl]sulfonyl]glycinamide;

N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-3-cyclohexyl-L-alanyl-2-oxo-(3S)-3-aminopentanoyl-N-[[2-chloro-5-[[(2-trifluoroethyl)amino]carbonyl]phenyl]sulfonyl]glycinamide;

N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-3-cyclohexyl-L- alanyl-2-oxo-(3S)-3-aminopentanoyl-N-[[2-chloro-5-[[(cyclopropylmethyl)amino]carbonyl]phenyl]sulfonyl] glycinamide;

N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-3-cyclohexyl-L-alanyl-2-oxo-(3S)-3-aminopentanoyl-N-[[3-nitro-4-(2-pyrimidinylthio)phenyl]sulfonyl]glycinamide;

N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-3-cyclohexyl-L-alanyl-2-oxo-(3S)-3-aminopentanoyl-N-[[2-chloro-4-(acetylamino)phenyl]sulfonyl]glycinamide;

N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-3-cyclohexyl-L-alanyl-2-oxo-(3S)-3-aminopentanoyl-N-[[3-chloro-4-(2-benzoxazolylthio)phenyl]sulfonyl]glycinamide;

N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-3-cyclohexyl-L-alanyl-2-oxo-(3 S)-3-amino pentanoyl-N-[[3,5-dichloro-4-(4-nitrophenoxy)phenyl]sulfonyl]glycinamide;

N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-3-cyclohexyl-L-alanyl-2-oxo-(3 S)-3-amino pentanoyl-N-[[5-(acetylamino)-1,3,4-thiadiazol-2-yl]sulfonyl]glycinamide;

N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-3-cyclohexyl-L-alanyl-2-oxo-(3 S)-3-amino pentanoyl-N-[(3-cyanophenyl)sulfonyl]glycinamide;

N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-3-cyclohexyl-L-alanyl-2-oxo-(3 S)-3-amino pentanoyl-N-[[3-(aminosulfonyl)-5-chlorophenyl]sulfonyl]glycinamide;

N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-3-cyclohexyl-L-alanyl-2-oxo-(3S)-3-amino pentanoyl-N-[[3,5-bis(trifluoromethyl)phenyl]sulfonyl]glycinamide;

N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-3-cyclohexyl-L-alanyl-2-oxo-(3S)-3-aminopentanoyl-N-[[4-[5-[3-(4-chlorophenyl)-3-oxo-1-propenyl]-2-furanyl]phenyl]sulfonyl]glycinamide;

N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-3-cyclohexyl-L-alanyl-2-oxo-(3S)-3-aminopentanoyl-N-[[3-[[(phenylmethyl)amino]carbonyl]phenyl]sulfonyl]glycinamide;

N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-3-cyclohexyl-L-alanyl-2-oxo-(3S)-3-aminopentanoyl-N-[[3-[[(2,2,2-trifluoroethyl)amino]carbonyl]phenyl]sulfonyl]glycinamide;

N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-3-cyclohexyl-L-alanyl-2-oxo-(3S)-3-aminopentanoyl-N-[[3-[(benzoylamino)sulfonyl]-5-chlorophenyl]sulfonyl]glycinamide;

N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-3-cyclohexyl-L-alanyl-5,5-difluoro-2-oxo-(3S)-3-aminopentanoylglycine;

(3S)-5,5-difluoro-2-oxo-3-[[N-(2-pyrazinylcarbonyl)- L-leucyl-L-isoleucyl-3-cyclohexyl-L-alanyl]amino]-N- (2H-tetrazol-5-ylmethyl)pentanamide;

N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-3-cyclohexyl-L-alanyl-5,5-difluoro-2-oxo-(3S)- 3-aminopentanoyl-N-[(3,5-dichlorophenyl)sulfonyl]glycinamide;

N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-3-cyclohexyl-L-alanyl-5,5-difluoro-2-oxo-(3S)-3-aminopentanoyl-N-[(3-chlorophenyl)sulfonyl]glycinamide;

N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-3-cyclohexyl-L-alanyl-5,5-difluoro-2-oxo-(3S)-3-aminopentanoyl-N-[5-(acetylamino)-1,3,4-thiadiazol-2-yl]sulfonyl]-glycinamide;

N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-3-cyclohexyl-L-alanyl-5,5-difluoro-2-oxo-(3S)-3-aminopentanoyl-N-(3-aminosulfonyl-5-chlorophenyl)sulfonyl]glycinamide;

(3S)-5,5,5-trifluoro-2-oxo-3-[[N-(2-pyrazinylcarbonyl)- L-leucyl-L-isoleucyl-3-cyclohexyl-L-alanyl]amino]- N-(2H-tetrazol-5-ylmethyl)pentanamide;

N-[4-*sec*-butyl-15-{[(3-chloro-5-{[(3,3,3-trifluoropropanoyl)amino]sulfonyl}phenyl)sulfonyl]amino}-7-(cyclohexylmethyl)-10-(2,2-difluoroethyl)-1-isobutyl-2,5,8,11,12,15-hexaoxo-3,6,9,13-tetraazapentadec-1-yl]-2-pyrazinecarboxamide;

N-[4-*sec*-butyl-15-[({3-chloro-5-[(hexanoylamino)sulfonyl]phenyl}sulfonyl)amino]-7-(cyclohexylmethyl)-10-(2,2-difluoroethyl)-1-isobutyl-2,5,8,11,12,15-hexaoxo-3,6,9,13-tetraazapentadec-1-yl]-2-pyrazinecarboxamide;

N-[15-[([1,1'-biphenyl]-3-ylsulfonyl)amino]-4-*sec*-butyl-7-(cyclohexylmethyl)-10-ethyl-1-isobutyl-2,5,8,11,12,15-hexaoxo-3,6,9,13-tetraazapentadec-1-yl]-2-pyrazinecarboxamide;

N-(4-*sec*-butyl-7-(cyclohexylmethyl)-10-ethyl-1-isobutyl-15-{[(4'-methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino}-2,5,8,11,12,15-hexaoxo-3,6,9,13-tetraazapentadec-1-yl)-2-pyrazinecarboxamide;

N-(4-*sec*-butyl-7-(cyclohexylmethyl)-15-{[(3',5'-dichloro[1,1'-biphenyl]-4-yl)sulfonyl]amino}-10-ethyl-1-isobutyl-2,5,8,11,12,15-hexaoxo-3,6,9,13-tetraazapentadec-1-yl)-2-pyrazinecarboxamide;

N-[4-*sec*-butyl-15-{[(4'-chloro[1,1'-biphenyl]-3-yl)sulfonyl]amino}-7-(cyclohexylmethyl)-10-(2,2-

difluoroethyl)-1-isobutyl-2,5,8,11,12,15-hexaoxo-3,6,9,13-tetraazapentadec-1-yl]-2-pyrazinecarboxamide;

N-[4-*sec*-butyl-7-(cyclohexylmethyl)-10-(2,2-difluoroethyl)-1-isobutyl-15-({[3-(2-methylphenoxy)phenyl]sulfonyl}amino)-2,5,8,11,12,15-hexaoxo-3,6,9,13-tetraazapentadec-1-yl]-2-pyrazinecarboxamide;

N-[4-*sec*-butyl-15-({[3-(2-chlorophenoxy)phenyl]sulfonyl}amino)-7-(cyclohexylmethyl)-10-(2,2-difluoroethyl)-1-isobutyl-2,5,8,11,12,15-hexaoxo-3,6,9,13-tetraazapentadec-1-yl]-2-pyrazinecarboxamide;

(3*S*,6*S*,9*S*,12*S*)-9-(cyclohexylmethyl)-12-(2,2-difluoroethyl)-3-isobutyl-6-[(1*R*)-1-methylpropyl]-1,4,7,10,13-pentaoxo-1-(2-pyrazinyl)-2,5,8,11-tetraazatetradecan-14-oic acid;

N-(4-*sec*-butyl-7-(cyclohexylmethyl)-10-(2,2-difluoroethyl)-1-isobutyl-15-{[(4'-methyl[1,1'-biphenyl]-3-yl)sulfonyl]amino}-2,5,8,11,12,15-hexaoxo-3,6,9,13-tetraazapentadec-1-yl)-2-pyrazinecarboxamide;

N-[15-({[3',5'-bis(trifluoromethyl)[1,1'-biphenyl]-3-yl]sulfonyl}amino)-4-*sec*-butyl-7-(cyclohexylmethyl)-10-(2,2-difluoroethyl)-1-isobutyl-2,5,8,11,12,15-hexaoxo-3,6,9,13-tetraazapentadec-1-yl]-2-pyrazinecarboxamide;

N-[4-*sec*-butyl-15-[({5-[(4-cyanobenzoyl)amino]-1,3,4-thiadiazol-2-yl}sulfonyl)amino]-7-(cyclohexylmethyl)-10-(2,2-difluoroethyl)-1-isobutyl-2,5,8,11,12,15-hexaoxo-3,6,9,13-tetraazapentadec-1-yl]-2-pyrazinecarboxamide;

N-[4-*sec*-butyl-15-[({5-[(2-chlorobenzoyl)amino]-1,3,4-thiadiazol-2-yl}sulfonyl)amino]-7-(cyclohexylmethyl)-10-(2,2-difluoroethyl)-1-isobutyl-2,5,8,11,12,15-hexaoxo-3,6,9,13-tetraazapentadec-1-yl]-2-pyrazinecarboxamide;

N-{4-*sec*-butyl-7-(cyclohexylmethyl)-10-(2,2-difluoroethyl)-1-isobutyl-15-[({5-[(4-methoxybenzoyl)amino]-1,3,4-thiadiazol-2-yl}sulfonyl)amino]-2,5,8,11,12,15-hexaoxo-3,6,9,13-tetraazapentadec-1-yl}-2-pyrazinecarboxamide;

N-{4-*sec*-butyl-7-(cyclohexylmethyl)-10-(2,2-difluoroethyl)-1-isobutyl-15-[({5-[(3-methoxybenzoyl)amino]-1,3,4-thiadiazol-2-yl}sulfonyl)amino]-2,5,8,11,12,15-hexaoxo-3,6,9,13-tetraazapentadec-1-yl}-2-pyrazinecarboxamide;

N-{4-*sec*-butyl-7-(cyclohexylmethyl)-10-(2,2-difluoroethyl)-15-[({5-[(3,5-dimethylbenzoyl)amino]-1,3,4-thiadiazol-2-yl}sulfonyl)amino]-1-isobutyl-2,5,8,11,12,15-hexaoxo-3,6,9,13-tetraazapentadec-1-yl}-2-pyrazinecarboxamide;

N-(4-*sec*-butyl-7-(cyclohexylmethyl)-10-(2,2-difluoroethyl)-1-isobutyl-2,5,8,11,12,15-hexaoxo-15-{[(3-phenoxyphenyl)sulfonyl]amino}-3,6,9,13-tetraazapentadec-1-yl)-2-pyrazinecarboxamide;

6-*sec*-butyl-9-(cyclohexylmethyl)-12-ethyl-3-isobutyl-1,4,7,10,13-pentaoxo-1-(2-pyrazinyl)-2,5,8,11-tetraazatetradecan-14-oic acid;

N-{4-*sec*-butyl-7-(cyclohexylmethyl)-10-(2,2-difluoroethyl)-1-isobutyl-15-[({5-[(3-methylbutanoyl)amino]-1,3,4-thiadiazol-2-yl}sulfonyl)amino]-2,5,8,11,12,15-hexaoxo-3,6,9,13-tetraazapentadec-1-yl}-2-pyrazinecarboxamide;

N-[4-*sec*-butyl-7-(cyclohexylmethyl)-10-(2,2-difluoroethyl)-15-({[5-(hexanoylamino)-1,3,4-thiadiazol-2-yl]sulfonyl}amino)-1-isobutyl-2,5,8,11,12,15-hexaoxo-3,6,9,13-tetraazapentadec-1-yl]-2-pyrazinecarboxamide;

methyl (3*S*,6*S*,9*S*,12*S*)-9-(cyclohexylmethyl)-12-(2,2-difluoroethyl)-3-isobutyl-6-[(1*R*)-1-methylpropyl]-1,4,7,10,13,14-hexaoxo-1-(2-pyrazinyl)-2,5,8,11,15-pentaazaheptadecan-17-oate;

N-[4-*sec*-butyl-15-{[(3-chloro-5-{[(3-chlorobenzoyl)amino]sulfonyl}phenyl)sulfonyl]amino}-7-(cyclohexylmethyl)-10-ethyl-1-isobutyl-2,5,8,11,12,15-hexaoxo-3,6,9,13-tetraazapentadec-1-yl]-2-pyrazinecarboxamide;

N-[4-*sec*-butyl-7-(cyclohexylmethyl)-10-(2,2-difluoroethyl)-1-isobutyl-2,5,8,11,12,15-hexaoxo-15-({[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]sulfonyl}amino)-3,6,9,13-tetraazapentadec-1-yl]-2-pyrazinecarboxamide;

N-[15-[([1,1'-biphenyl]-3-ylsulfonyl)amino]-4-*sec*-butyl-7-(cyclohexylmethyl)-10-(2,2-difluoroethyl)-1-isobutyl-2,5,8,11,12,15-hexaoxo-3,6,9,13-tetraazapentadec-1-yl]-2-pyrazinecarboxamide;

N-[4-*sec*-butyl-15-[({5-[(4-*tert*-butylbenzoyl)amino]-1,3,4-thiadiazol-2-yl}sulfonyl)amino]-7-(cyclohexylmethyl)-10-(2,2-difluoroethyl)-1-isobutyl-2,5,8,11,12,15-hexaoxo-3,6,9,13-tetraazapentadec-1-yl]-2-pyrazinecarboxamide;

N-[4-*sec*-butyl-15-{[(3-chloro-5-{[(3-methylbutanoyl)amino]sulfonyl}phenyl)sulfonyl]amino}-7-(cyclohexylmethyl)-10-(2,2-difluoroethyl)-1-isobutyl-2,5,8,11,12,15-hexaoxo-3,6,9,13-tetraazapentadec-1-yl]-2-pyrazinecarboxamide;

N-{(1*S*,4*S*,7*S*,10*S*)-7-(cyclohexylmethyl)-10-(2,2-difluoroethyl)-1-isobutyl-14-[4-(4-methoxyphenyl)-5-(trifluoromethyl)-4*H*-1,2,4-triazol-3-yl]-4-[(1*R*)-1-methylpropyl]-2,5,8,11,12-pentaoxo-3,6,9,13-tetraazatetradec-1-yl}-2-pyrazinecarboxamide;

N-{4-*sec*-butyl-7-(cyclohexylmethyl)-10-(2,2-difluoroethyl)-15-[({5-[(4-ethylbenzoyl)amino]-1,3,4-thiadiazol-2-yl}sulfonyl)amino]-1-isobutyl-2,5,8,11,12,15-hexaoxo-3,6,9,13-tetraazapentadec-1-yl}-2-pyrazinecarboxamide;

N-[4-*sec*-butyl-15-[({5-[(4-chlorobenzoyl)amino]-1,3,4-thiadiazol-2-yl}sulfonyl)amino]-7-(cyclohexylmethyl)-10-(2,2-difluoroethyl)-1-isobutyl-2,5,8,11,12,15-hexaoxo-3,6,9,13-tetraazapentadec-1-yl]-2-pyrazinecarboxamide;

N-[4-*sec*-butyl-7-(cyclohexylmethyl)-15-[({5-[(3,5-difluorobenzoyl)amino]-1,3,4-thiadiazol-2-yl}sulfonyl)amino]-10-(2,2-difluoroethyl)-1-isobutyl-2,5,8,11,12,15-hexaoxo-3,6,9,13-tetraazapentadec-1-yl]-2-pyrazinecarboxamide;

N-[4-*sec*-butyl-15-[({5-[(3-chlorobenzoyl)amino]-1,3,4-thiadiazol-2-yl}sulfonyl)amino]-7-(cyclohexylmethyl)-10-(2,2-difluoroethyl)-1-isobutyl-2,5,8,11,12,15-hexaoxo-3,6,9,13-tetraazapentadec-1-yl]-2-pyrazinecarboxamide;

N-{(1*S*,4*S*,7*S*,10*S*)-7-(cyclohexylmethyl)-10-ethyl-1-isobutyl-4-[(1*R*)-1-methylpropyl]-2,5,8,11,12-pentaoxo-3,6,9,13-tetraazahexadec-15-en-1-yl}-2-pyrazinecarboxamide;

N-{(1*S*,4*S*,7*S*,10*S*)-7-(cyclohexylmethyl)-10-ethyl-1-isobutyl-4-[(1*R*)-1-methylpropyl]-2,5,8,11,12-pentaoxo-3,6,9,13-tetraazahexadec-15-yn-1-yl}-2-pyrazinecarboxamide;

tert-butyl (3*S*,6*S*,9*S*,12*S*)-9-(cyclohexylmethyl)-12-ethyl-3-isobutyl-6-[(1*R*)-1-methylpropyl]-1,4,7,10,13,14-hexaoxo-1-(2-pyrazinyl)-2,5,8,11,15-pentaazaheptadecan-17-oate;

N-{(1*S*,4*S*,7*S*,10*S*)-7-(cyclohexylmethyl)-10-ethyl-1-isobutyl-4-[(1*R*)-1-methylpropyl]-2,5,8,11,12-pentaoxo-14-phenyl-3,6,9,13-tetraazatetradec-1-yl}-2-pyrazinecarboxamide

N-((1*S*)-1-{[((1*S*,2*R*)-1-{[((1*S*)-1-(cyclohexylmethyl)-2-{[(1*S*)-1-ethyl-2,3-dioxo-3-(1-pyrrolidinyl)propyl]amino}-2-oxoethyl)amino]carbonyl}-2-methylbutyl)amino]carbonyl}-3-methylbutyl)-2-pyrazinecarboxamide;

N-{(1*S*,4*S*,7*S*,10*S*)-7-(cyclohexylmethyl)-10-ethyl-15,15,15-trifluoro-1-isobutyl-4-[(1*R*)-1-methylpropyl]-2,5,8,11,12-pentaoxo-3,6,9,13-tetraazapentadec-1-yl}-2-pyrazinecarboxamide;

N-{(1*S*,4*S*,7*S*,10*S*)-15-amino-7-(cyclohexylmethyl)-10-ethyl-1-isobutyl-4-[(1*R*)-1-methylpropyl]-2,5,8,11,12,15-hexaoxo-3,6,9,13-tetraazapentadec-1-yl}-2-pyrazinecarboxamide;

(3*S*,6*S*,9*S*,12*S*,16*S*)-9-(cyclohexylmethyl)-12-ethyl-3-isobutyl-16-methyl-6-[(1*R*)-1-methylpropyl]-1,4,7,10,13,14-hexaoxo-1-(2-pyrazinyl)-2,5,8,11,15-pentaazaheptadecan-17-oic acid;

N-[9-*sec*-butyl-6-(cyclohexylmethyl)-3-ethyl-12-isobutyl-2,5,8,11,14-pentaoxo-14-(2-pyrazinyl)-4,7,10,13-tetraazatetradec-1-anoyl]aspartic acid;

(3*S*,6*S*,9*S*,12*S*)-9-(cyclohexylmethyl)-12-ethyl-3-isobutyl-6-[(1*R*)-1-methylpropyl]-1,4,7,10,13,14-hexaoxo-1-(2-pyrazinyl)-2,5,8,11,15-pentaazaoctadecan-18-oic acid;

1,1-dimethylethyl N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-(4R)-4-(phenylmethoxy)-L- prolyl-5,5-difluoro-2-oxo-(3S)-3-aminopentanoylglycine;

N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-(4R)-4-(phenylmethoxy)-L-prolyl-5,5-di fluoro-2-oxo-(3S)-3-aminopentanoylglycine;

(4R)-1-[N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl]- N-[(1S)-1-(2,2-difluoroethyl)-2,3-dioxo-3-[(2H)-tetrazol-5-yl methyl)amino]propyl]-4-(phenylmethoxy)-L-prolinamide;

(4R)-N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-N-[(1S)-1-(2,2-difluoroethyl)-3-methoxy-2,3-dioxopropyl]-4-(phenylmethoxy)-L-prolinamide;

N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-(4R)-4-(phenylmethoxy)-L-prolyl-5,5-difluoro-2-oxo-(3S)-3-aminopentanoyl-N-[(3-chlorophenyl)sulfonyl]glycinamide;

N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-(4R)-4-(phenylmethoxy)-L-prolyl-5,5-difluoro-2-oxo-(3S)-3-aminopentanoyl-N-[(5-carboxy-2-chlorophenyl)-sulfonyl]glycinamide;

N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-(4R)-4-(phenylmethoxy)-L-prolyl-5,5-difluoro-2-oxo-(3S)-3-aminopentanoyl-N-[(5-acetylamino)1,3,4-thiadiazol-2-yl)sulfonyl]glycinamide;

N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-(4R)-4-(phenylmethoxy)-L-prolyl-5,5-difluoro-2-oxo-(3S)-3-aminopentanoyl-N-[3,5-dichlorophenyl) sulfonyl]glycinamide;

N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-(4R)-4-(phenylmethoxy)-L-prolyl-5,5-difluoro-2-oxo-(3S)-3-aminopentanoyl N-(4-methyl-3-nitrophenyl)sulfonyl]-glycinamide;

N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-(4R)-4-(phenylmethoxy)-L-prolyl-5,5-difluoro-2-oxo-(3S)-3-aminopentanoyl N-(3-carboxyl-4-chloro-2-fluorophenyl)sulfonyl]-glycinamide;

N-(2-pyrazinylcarbonyl)-L-leucyl-L-isoleucyl-(4R)-4-(phenylmethoxy)-L-prolyl-5,5-difluoro-2-oxo-(3S)-3-aminopentanoyl N-[(3-chloro-4-acetylamino)phenyl]sulfonyl]-glycinamide;

N-((1*S*)-1-{[((1*S*,2*R*)-1-{[(2*S*,4*R*)-2-({[(1*S*)-3-({2-[({3-[(benzoylamino)sulfonyl]-5-chlorophenyl}sulfonyl)amino]-2-oxoethyl}amino)-1-(2,2-difluoroethyl)-2,3-dioxopropyl]amino}carbonyl)-4-(benzyloxy)pyrrolidinyl]carbonyl}-2-

methylbutyl)amino]carbonyl}-3-methylbutyl)-2-pyrazinecarboxamide;

tert-butyl ({(3*S*)-3-[({(2*S*,4*R*)-4-(benzyloxy)-1-[(2*S*)-3-methyl-2-({(2*S*)-3-methyl-2-[(2-pyrazinylcarbonyl)amino]butanoyl}amino)butanoyl]pyrrolidinyl}carbonyl)amino]-5,5-difluoro-2-oxopentanoyl}amino)acetate;

N-((1*S*)-1-{[((1*S*,2*R*)-1-{[(2*S*,4*R*)-4-(benzyloxy)-2-({[(1*S*)-3-[(2-{[(3-chloro-4-methylphenyl)sulfonyl]amino}-2-oxoethyl)amino]-1-(2,2-difluoroethyl)-2,3-dioxopropyl]amino}carbonyl)pyrrolidinyl]carbonyl}-2-methylbutyl)amino]carbonyl}-3-methylbutyl)-2-pyrazinecarboxamide;

N-((1*S*)-1-{[((1*S*,2*R*)-1-{[(2*S*,4*R*)-4-(benzyloxy)-2-({[(1*S*)-3-({2-[({5-[(3-chlorobenzoyl)amino]-1,3,4-thiadiazol-2-yl}sulfonyl)amino]-2-oxoethyl}amino)-1-(2,2-difluoroethyl)-2,3-dioxopropyl]amino}carbonyl)pyrrolidinyl]carbonyl}-2-methylbutyl)amino]carbonyl}-3-methylbutyl)-2-pyrazinecarboxamide;

methyl ({(3*S*)-3-[({(2*S*,4*R*)-4-(benzyloxy)-1-[(2*S*,3*R*)-3-methyl-2-({(2*S*)-4-methyl-2-[(2-pyrazinylcarbonyl)amino]pentanoyl}amino)pentanoyl]pyrrolidinyl}carbonyl)amino]-5,5-difluoro-2-oxopentanoyl}amino)acetate;

N-((1*S*)-1-{[((1*S*,2*R*)-1-{[(2*S*,4*R*)-4-(benzyloxy)-2-({[(1*S*)-3-[(2-{[(2,4-dichloro-5-methylphenyl)sulfonyl]amino}-2-oxoethyl)amino]-1-(2,2-difluoroethyl)-2,3-dioxopropyl]amino}carbonyl)pyrrolidinyl]carbonyl}-2-methylbutyl)amino]carbonyl}-3-methylbutyl)-2-pyrazinecarboxamide;

N-[(1*S*)-1-({[(1*S*,2*R*)-1-({(2*S*,4*R*)-4-(benzyloxy)-2-[({(1*S*)-1-(2,2-difluoroethyl)-3-[(2-{[(3,4-

difluorophenyl)sulfonyl]amino}-2-oxoethyl)amino]-2,3-dioxopropyl}amino)carbonyl]pyrrolidinyl}carbonyl)-2-methylbutyl]amino}carbonyl)-3-methylbutyl]-2-pyrazinecarboxamide;

methyl 5-({[({(3*S*)-3-[({(2*S*,4*R*)-4-(benzyloxy)-1-[(2*S*,3*R*)-3-methyl-2-({(2*S*)-4-methyl-2-[(2-pyrazinylcarbonyl)amino]pentanoyl}amino)pentanoyl]pyrrolidinyl}carbonyl)amino]-5,5-difluoro-2-oxopentanoyl}amino)acetyl]amino}sulfonyl)-2,4-dichlorobenzoate;

N-{(1*S*)-1-[({(1*S*,2*R*)-1-[((2*S*,4*R*)-4-(benzyloxy)-2-{[((1*S*)-1-(2,2-difluoroethyl)-3-{[2-({[4-(3,5-dimethyl-1-piperidinyl)-3-nitrophenyl]sulfonyl}amino)-2-oxoethyl]amino}-2,3-dioxopropyl)amino]carbonyl}pyrrolidinyl)carbonyl]-2-methylbutyl}amino)carbonyl]-3-methylbutyl}-2-pyrazinecarboxamide;

N-[(1*S*)-1-({[(1*S*,2*R*)-1-({(2*S*,4*R*)-4-(benzyloxy)-2-[({(1*S*)-1-(2,2-difluoroethyl)-3-[(2-{[(3-nitrophenyl)sulfonyl]amino}-2-oxoethyl)amino]-2,3-dioxopropyl}amino)carbonyl]pyrrolidinyl}carbonyl)-2-methylbutyl]amino}carbonyl)-3-methylbutyl]-2-pyrazinecarboxamide;

N-{(1*S*)-1-[({(1*S*,2*R*)-1-[((2*S*,4*R*)-4-(benzyloxy)-2-{[((1*S*)-1-(2,2-difluoroethyl)-3-{[2-({[5-(hexanoylamino)-1,3,4-thiadiazol-2-yl]sulfonyl}amino)-2-oxoethyl]amino}-2,3-dioxopropyl)amino]carbonyl}pyrrolidinyl)carbonyl]-2-methylbutyl}amino)carbonyl]-3-methylbutyl}-2-pyrazinecarboxamide;

5-({[({(3*S*)-3-[({(2*S*,4*R*)-4-(benzyloxy)-1-[(2*S*,3*R*)-3-methyl-2-({(2*S*)-4-methyl-2-[(2-pyrazinylcarbonyl)amino]pentanoyl}amino)pentanoyl]pyrrolidinyl}carbonyl)amino]-5,5-difluoro-2-

oxopentanoyl}amino)acetyl]amino}sulfonyl)-2,4-dichlorobenzoic acid;

N-[[5-(4-chlorophenyl)-2-furanyl]carbonyl]-L-isoleucyl-3-cyclohexylalanyl-2-oxo-3-aminopentanoylglycine;

N-[[5-(4-chlorophenyl)-2-furanyl]carbonyl]-Lisoleucyl-3-cyclohexylalanyl-2-oxo-3-aminopentanoyl-N-[(trifluoromethyl)sulfonyl]glycinamide;

N-[[5-(4-chlorophenyl)-2-furanyl]carbonyl]-Lisoleucyl-3-cyclohexylalanyl-2-oxo-3-aminopentanoyl-N-[(3,5-dichlorophenyl)sulfonyl]glycinamide;

N-[[5-(4-chlorophenyl)-2-furanyl]carbonyl]-Lisoleucyl-3-cyclohexylalanyl-2-oxo-3-aminopentanoyl-N-[(3-nitrophenyl)sulfonyl]glycinamide;

(4R)-1-[[5-(4-chlorophenyl)-2-furanyl]carbonyl-L-isoleucyl-N-[(1S)-1-(2,2-difluoroethyl)-2,3-dioxo-3-[(2H-tetrazol-5-ylmethyl)amino]propyl]-4-(phenylmethoxy)-L-prolinamide;

(2*S*,4*R*)-4-(benzyloxy)-*N*-{(1*S*)-1-(2,2-difluoroethyl)-2,3-dioxo-3-[(2*H*-tetraazol-5-ylmethyl)amino]propyl}-1-((2*S*,3*R*)-3-methyl-2-{[(9-oxo-9*H*-fluoren-1-yl)carbonyl]amino}pentanoyl)-2-pyrrolidinecarboxamide;

tert-butyl {[(3*S*)-3-({[(2*S*,4*R*)-4-(benzyloxy)-1-((2*S*,3*R*)-3-methyl-2-{[(9-oxo-9*H*-fluoren-1-yl)carbonyl]amino}pentanoyl)pyrrolidinyl]carbonyl}amino)-5,5-difluoro-2-oxopentanoyl]amino}acetate;

{[(3*S*)-3-({[(2*S*,4*R*)-4-(benzyloxy)-1-((2*S*,3*R*)-3-methyl-2-{[(9-oxo-9*H*-fluoren-1-yl)carbonyl]amino}pentanoyl)pyrrolidinyl]carbonyl}amino)-5,5-difluoro-2-oxopentanoyl]amino}acetic acid;

(2*S*,4*R*)-*N*-[(1*S*)-3-{[2-({[5-(acetylamino)-1,3,4-thiadiazol-2-yl]sulfonyl}amino)-2-oxoethyl]amino}-1-(2,2-difluoroethyl)-2,3-dioxopropyl]-4-(benzyloxy)-1-((2*S*,3*R*)-3-methyl-2-{[(9-oxo-9*H*-fluoren-1-yl)carbonyl]amino}pentanoyl)-2-pyrrolidinecarboxamide;

(2*S*,4*R*)-4-(benzyloxy)-*N*-((1*S*)-1-(2,2-difluoroethyl)-3-{[2-({[5-(hexanoylamino)-1,3,4-thiadiazol-2-yl]sulfonyl}amino)-2-oxoethyl]amino}-2,3-dioxopropyl)-1-((2*S*,3*R*)-3-methyl-2-{[(9-oxo-9*H*-fluoren-1-yl)carbonyl]amino}pentanoyl)-2-pyrrolidinecarboxamide;

((2*S*,4*R*)-4-(benzyloxy)-*N*-[(1*S*)-3-({2-[({5-[(4-chlorobenzoyl)amino]-1,3,4-thiadiazol-2-yl}sulfonyl)amino]-2-oxoethyl}amino)-1-(2,2-difluoroethyl)-2,3-dioxopropyl]-1-((2*S*,3*R*)-3-methyl-2-{[(9-oxo-9*H*-fluoren-1-yl)carbonyl]amino}pentanoyl)-2-pyrrolidinecarboxamide;

(2*S*,4*R*)-4-(benzyloxy)-*N*-[(1*S*)-1-(2,2-difluoroethyl)-3-({2-[({5-[(4-ethylbenzoyl)amino]-1,3,4-thiadiazol-2-yl}sulfonyl)amino]-2-oxoethyl}amino)-2,3-dioxopropyl]-1-((2*S*,3*R*)-3-methyl-2-{[(9-oxo-9*H*-fluoren-1-yl)carbonyl]amino}pentanoyl)-2-pyrrolidinecarboxamide;

tert-butyl {[(3*S*)-3-({[(2*S*,4*R*)-4-(benzyloxy)-1-((2*S*,3*R*)-2-{[5-(4-chlorophenyl)-2-furoyl]amino}-3-methylpentanoyl)pyrrolidinyl]carbonyl}amino)-5,5-difluoro-2-oxopentanoyl]amino}acetate;

{[(3*S*)-3-({[(2*S*,4*R*)-4-(benzyloxy)-1-((2*S*,3*R*)-2-{[5-(4-chlorophenyl)-2-furoyl]amino}-3-methylpentanoyl)pyrrolidinyl]carbonyl}amino)-5,5-difluoro-2-oxopentanoyl]amino}acetic acid;

(2*S*,4*R*)-*N*-[(1*S*)-3-{[2-({[5-(acetylamino)-1,3,4-thiadiazol-2-yl]sulfonyl}amino)-2-oxoethyl]amino}-1-(2,2-difluoroethyl)-2,3-dioxopropyl]-4-(benzyloxy)-1-((2*S*,3*R*)-2-

{[5-(4-chlorophenyl)-2-furoyl]amino}-3-methylpentanoyl)-2-pyrrolidinecarboxamide;

(2*S*,4*R*)-4-(benzyloxy)-*N*-[(1*S*)-3-({2-[({5-[(3-chlorobenzoyl)amino]-1,3,4-thiadiazol-2-yl}sulfonyl)amino]-2-oxoethyl}amino)-1-(2,2-difluoroethyl)-2,3-dioxopropyl]-1-((2*S*,3*R*)-2-{[5-(4-chlorophenyl)-2-furoyl]amino}-3-methylpentanoyl)-2-pyrrolidinecarboxamide;

(2*S*,4*R*)-4-(benzyloxy)-*N*-[(1*S*)-3-({2-[([1,1'-biphenyl]-3-ylsulfonyl)amino]-2-oxoethyl}amino)-1-(2,2-difluoroethyl)-2,3-dioxopropyl]-1-((2*S*,3*R*)-2-{[5-(4-chlorophenyl)-2-furoyl]amino}-3-methylpentanoyl)-2-pyrrolidinecarboxamide;

N-{(1*S*,4*S*,7*S*)-10-allyl-7-(cyclohexylmethyl)-1-isobutyl-4-[(1*R*)-1-methylpropyl]-2,5,8,11,12-pentaoxo-3,6,9,13-tetraazahexadec-15-en-1-yl}-2-pyrazinecarboxamide;

(6*S*,9*S*,12*S*)-*N*,3-diallyl-6-(cyclohexylmethyl)-12-isobutyl-9-[(1*R*)-1-methylpropyl]-2,5,8,11,14-pentaoxo-16,16-diphenyl-4,7,10,13-tetraazahexadecan-1-amide;

(4*S*,7*S*,10*S*)-*N*,13-diallyl-10-(cyclohexylmethyl)-4-isobutyl-7-[(1*R*)-1-methylpropyl]-2,5,8,11,14-pentaoxo-3,6,9,12-tetraazapentadecan-15-amide;

N-{(1*S*,4*S*,7*S*)-10-allyl-7-(cyclohexylmethyl)-1-isobutyl-4-[(1*R*)-1-methylpropyl]-2,5,8,11,12-pentaoxo-3,6,9,13-tetraazahexadec-15-en-1-yl}-2-pyridinecarboxamide;

N-{(1*S*,4*S*,7*S*)-10-allyl-7-(cyclohexylmethyl)-1-isobutyl-4-[(1*R*)-1-methylpropyl]-2,5,8,11,12-pentaoxo-3,6,9,13-tetraazahexadec-15-en-1-yl}nicotinamide;

N-{(1*S*,4*S*,7*S*)-10-allyl-7-(cyclohexylmethyl)-1-isobutyl-4-[(1*R*)-1-methylpropyl]-2,5,8,11,12-pentaoxo-3,6,9,13-tetraazahexadec-15-en-1-yl}-4-nitro-1*H*-pyrazole-3-carboxamide;

2-{(3*S*,6*S*,9*S*)-12-allyl-9-(cyclohexylmethyl)-3-isobutyl-6-[(1*R*)-1-methylpropyl]-4,7,10,13,14-pentaoxo-2,5,8,11,15-pentaazaoctadec-17-en-1-anoyl}benzoic acid;

N-[4-*sec*-butyl-7-(cyclohexylmethyl)-10-ethyl-1-isobutyl-2,5,8,11,12-pentaoxo-3,6,9,13-tetraazahexadec-15-en-1-yl]nicotinamide;

N-allyl-9-*sec*-butyl-6-(cyclohexylmethyl)-3-ethyl-12-isobutyl-2,5,8,11,14-pentaoxo-16,16-diphenyl-4,7,10,13-tetraazahexadecan-1-amide;

({3-[({1-[3-methyl-2-({4-methyl-2-[(2-pyrazinylcarbonyl)amino]pentanoyl}amino)pentanoyl]-octahydro-1*H*-indol-2-yl}carbonyl)amino]-2-oxopentanoyl}amino)acetic acid;

tert-butyl ({3-[({1-[3-methyl-2-({4-methyl-2-[(2-pyrazinylcarbonyl)amino]pentanoyl}amino)-pentanoyl]octahydro-1*H*-indol-2-yl}carbonyl)amino]-2-oxopentanoyl}amino)acetate; and

(3*S*,6*S*,9*S*,12*S*)-6-(cyclohexylmethyl)-3-ethyl-12-isobutyl-9-[(1*R*)-1-methylpropyl]-2,5,8,11,14-pentaoxo-16,16-diphenyl-4,7,10,13-tetraazahexadecan-1-oic acid;

or a pharmaceutically acceptable salt form thereof.

8. A compound according to Claim 1, wherein

Q is $-(CR^{10}R^{10c})_n-Q^1$ or

an amino acid residue, wherein the amino acid residue comprises a natural, a modified or an unnatural amino acid.

9. A compound according to Claim 8, wherein the compound is of Formula (IIb):



(IIb)

or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein;

R^{10} is selected from the group: $-CO_2R^{11}$, $-NR^{11}R^{11}$, and C_1-C_6 alkyl substituted with 0-1 R^{10a};

R^{10a} is selected from the group: halo, $-NO_2$, $-CN$, $-CF_3$, $-CO_2R^{11}$, $-NR^{11}R^{11}$, $-OR^{11}$, $-SR^{11}$, $-C(=NH)NH_2$, and aryl substituted with 0-1 R^{10b};

R^{10b} is selected from the group: $-CO_2H$, $-NH_2$, $-OH$, $-SH$, and $-C(=NH)NH_2$;

R^{10c} is H or C_1-C_4 alkyl;

alternatively, R^{10} and R^{10c} can be combined to form a C_3-C_6 cycloalkyl group substituted with 0-1 R^{10a};

R^{11} is, at each occurrence, independently H or C_1-C_4 alkyl;

R^{11a} is H, C_1-C_4 alkyl, C_1-C_4 haloalkyl, C_2-C_4 alkenyl, C_2-C_4 alkynyl, aryl, aryl(C_1-C_4 alkyl)-, C_3-C_6 cycloalkyl, or C_3-C_6 cycloalkyl(C_1-C_4 alkyl)-;

Q^1 is selected from
$-CO_2R^{11}$, $-SO_2R^{11}$, $-SO_3R^{11}$, $-P(O)_2R^{11}$, $-P(O)_3R^{11}$,
aryl substituted with 0-4 Q^{1a},
5-6 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group:

O, S, and N, said heterocyclic group substituted with 0-4 Q^{1a};

Q^{1a} is H, F, Cl, Br, I, $-NO_2$, -CN, -NCS, $-CF_3$, $-OCF_3$, $-CH_3$, $-OCH_3$, $-CO_2R^{19}$, $-C(=O)NR^{19}R^{19}$, $-NHC(=O)R^{19}$, $-SO_2R^{19}$, $-SO_2NR^{19}R^{19}$, $-NR^{19}R^{19}$, $-OR^{19}$, $-SR^{19}$, C_1-C_4 alkyl, C_1-C_4 alkoxy, C_1-C_4 haloalkyl, or C_1-C_4 haloalkoxy;

R^{19} is C_1-C_4 alkyl, C_1-C_4 haloalkyl, aryl, aryl(C_1-C_4 alkyl), C_3-C_6 cycloalkyl, or C_3-C_6 cycloalkyl(C_1-C_4 alkyl);

alternatively, $NR^{19}R^{19}$ may form a 5-6 membered heterocyclic group consisting of carbon atoms, a nitrogen atom, and optionally a second heteroatom selected from the group: O, S, and N;

A^2 is a bond, $-NH-CR^3R^4-C(=O)-$, an amino acid residue,



or



;

A^3 is a bond, $-NH-CR^5R^6-C(=O)-$, or an amino acid residue;

A^4 is a bond, $-NH-CR^7R^8-C(=O)-$, or an amino acid residue;

A^5 is a bond or an amino acid residue;

A^7 is a bond or an amino acid residue;

A^8 is an amino acid residue;

A^9 is an amino acid residue;

R^1 is selected from the group: H, F,

C_1-C_6 alkyl substituted with 0-3 R^{1a},
C_2-C_6 alkenyl substituted with 0-3 R^{1a},
C_2-C_6 alkynyl substituted with 0-3 R^{1a}, and
C_3-C_6 cycloalkyl substituted with 0-3 R^{1a};

R^{1a} is selected at each occurrence from the group:
Cl, F, Br, I, CF_3, CHF_2, OH, =O, SH,
$-CO_2R^{1b}$, $-SO_2R^{1b}$, $-SO_3R^{1b}$, $-P(O)_2R^{1b}$, $-P(O)_3R^{1b}$,
$-C(=O)NHR^{1b}$, $-NHC(=O)R^{1b}$, $-SO_2NHR^{1b}$, $-OR^{1b}$, $-SR^{1b}$,
C_1-C_3 alkyl, C_3-C_6 cycloalkyl, C_1-C_6 alkoxy,
$-S-(C_1$-C_6 alkyl),
aryl substituted with 0-5 R^{1c},
$-O-(CH_2)_q$-aryl substituted with 0-5 R^{1c},
$-S-(CH_2)_q$-aryl substituted with 0-5 R^{1c}, and
5-10 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N, and substituted with 0-3 R^{1c};

R^{1b} is H,
C_1-C_4 alkyl substituted with 0-3 R^{1c},
C_2-C_4 alkenyl substituted with 0-3 R^{1c},
C_2-C_4 alkynyl substituted with 0-3 R^{1c},
C_3-C_6 cycloalkyl substituted with 0-5 R^{1c},
C_3-C_6 carbocyle substituted with 0-5 R^{1c},
aryl substituted with 0-5 R^{1c}, or
5-6 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N, said heterocyclic group substituted with 0-4 R^{1c};

R^{1c} is selected at each occurrence from: C_1-C_4 alkyl, Cl, F, Br, I, OH, C_1-C_4 alkoxy, -CN, $-NO_2$, $C(O)OR^{1d}$, $NR^{1d}R^{1d}$, CF_3, and OCF_3;

R^{1d} is H or C_1-C_4 alkyl;

R^2 is H, F, or C_1-C_4 alkyl;

R^3 is selected from the group: H,
C_1-C_6 alkyl substituted with 0-4 R^{3a},
C_2-C_6 alkenyl substituted with 0-4 R^{3a},
C_2-C_6 alkynyl substituted with 0-4 R^{3a},
$-(CH_2)_q$- C_3-C_6 cycloalkyl substituted with 0-4 R^{3b},
$-(CH_2)_q$-aryl substituted with 0-5 R^{3b}, and
$-(CH_2)_q$-5-10 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N, and said heterocyclic group is substituted with 0-2 R^{3b};

R^{3a} is selected from the group: $-CO_2R^{11}$, $-NR^{11}R^{11}$, $-OR^{11}$, $-SR^{11}$, $-C(=NH)NH_2$, and aryl substituted with R^{10b};

R^{3b} is selected from the group: $-CO_2H$, $-NH_2$, -OH, -SH, and $-C(=NH)NH_2$;

R^{3c} is, at each occurrence, independently selected from: H, C_1-C_6 alkyl, -OH, and OR^{3d};

R^{3d} is C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, $-(CH_2)_q$- C_3-C_6 cycloalkyl, $-(CH_2)_q$-aryl, or $-(CH_2)_q$-(5-10 membered heterocyclic group), wherein said heterocyclic group consists of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N;

R^4 is selected from the group: H, C_1-C_6 alkyl, phenyl, phenylmethyl-, phenylethyl-, C_3-C_6 cycloalkyl, C_3-C_6 cycloalkylmethyl-, and C_3-C_6 cycloalkylethyl-;

R^5 and R^7 are independently H or R^3;

R^6 and R^8 are independently H or R^4;

R^9 is selected from the group: $-S(=O)R^{9a}$, $-S(=O)_2R^{9a}$, $-C(=O)R^{9a}$, $-C(=O)OR^{9a}$, $-C(=O)NHR^{9a}$, C_1-C_3 alkyl-R^{9a}, C_2-C_6 alkenyl-R^{9a}, and C_2-C_6 alkynyl-R^{9a};

R^{9a} is selected from the group:
C_1-C_6 alkyl substituted with 0-3 R^{9b},
C_3-C_6 cycloalkyl substituted with 0-3 R^{9c},
aryl substituted with 0-3 R^{9c}, and
5-14 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N, and said heterocyclic group is substituted with 0-3 R^{9c};

R^{9b} is selected from the group: phenyl, naphthyl, benzyl, and 5-10 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N, and R^{9b} is substituted with 0-3 R^{9c};

R^{9c} is selected at each occurrence from the group:
CF_3, OCF_3, Cl, F, Br, I, =O, OH, phenyl, $C(O)OR^{11}$, NH_2, $NH(CH_3)$, $N(CH_3)_2$, -CN, NO_2;
C_1-C_4 alkyl substituted with 0-3 R^{9d},
C_1-C_4 alkoxy substituted with 0-3 R^{9d},
C_3-C_6 cycloalkyl substituted with 0-3 R^{9d},
aryl substituted with 0-5 R^{9d}, and
5-6 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N, and said heterocyclic group is substituted with 0-4 R^{9d};

R^{9d} is selected at each occurrence from the group: C_1-C_4 alkyl, C_1-C_4 alkoxy, CF_3, OCF_3, Cl, F, Br, I, =O, OH, phenyl, $C(O)OR^{11}$, NH_2, $NH(CH_3)$, $N(CH_3)_2$, -CN, and NO_2;

n is 1, 2, or 3; and

p is 1 or 2; and

q, at each occurence, is independently 0, 1 or 2.

10. A compound according to Claim 3, wherein

R^{10} is selected from the group: $-CO_2R^{11}$, $-NR^{11}R^{11}$, and C_1-C_6 alkyl substituted with 0-1 R^{10a};

R^{10a} is selected from the group: halo, $-NO_2$, -CN, $-CF_3$, $-CO_2R^{11}$, $-NR^{11}R^{11}$, $-OR^{11}$, $-SR^{11}$, $-C(=NH)NH_2$, and aryl substituted with 0-1 R^{10b};

R^{10b} is selected from the group: $-CO_2H$, $-NH_2$, -OH, -SH, and $-C(=NH)NH_2$;

R^{10c} is H or C_1-C_4 alkyl;

alternatively, R^{10} and R^{10c} can be combined to form a C_3-C_6 cycloalkyl group substituted with 0-1 R^{10a};

R^{11} is, at each occurrence, independently H or C_1-C_4 alkyl;

R^{11a} is H, C_1-C_4 alkyl, C_1-C_4 haloalkyl, C_2-C_4 alkenyl, C_2-C_4 alkynyl, aryl, aryl(C_1-C_4 alkyl)-, C_3-C_6 cycloalkyl, or C_3-C_6 cycloalkyl(C_1-C_4 alkyl)-;

Q^1 is selected from

$-CO_2R^{11}$, $-SO_2R^{11}$, $-SO_3R^{11}$, $-P(O)_2R^{11}$, $-P(O)_3R^{11}$,
aryl substituted with 0-4 Q^{1a}, and
5-6 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N, said heterocyclic group substituted with 0-4 Q^{1a};

Q^{1a} is H, F, Cl, Br, I, $-NO_2$, -CN, -NCS, $-CF_3$, $-OCF_3$, $-CH_3$, $-OCH_3$, $-CO_2R^{19}$, $-C(=O)NR^{19}R^{19}$, $-NHC(=O)R^{19}$, $-SO_2R^{19}$, $-SO_2NR^{19}R^{19}$, $-NR^{19}R^{19}$, $-OR^{19}$, $-SR^{19}$, C_1-C_4 alkyl, C_1-C_4 alkoxy, C_1-C_4 haloalkyl, or C_1-C_4 haloalkoxy;

R^{19} is C_1-C_4 alkyl, C_1-C_4 haloalkyl, aryl, aryl(C_1-C_4 alkyl), C_3-C_6 cycloalkyl, or C_3-C_6 cycloalkyl(C_1-C_4 alkyl);

alternatively, $NR^{19}R^{19}$ may form a piperidinyl, piperazinyl, or morpholinyl group;

A^2 is a bond, $-NH-CR^3R^4-C(=O)-$, an amino acid residue,



or


;

A^3 is a bond or an amino acid residue;

A^4 is a bond or an amino acid residue;

A^5 is a bond;

R^1 is selected from the group: H,
C_1-C_6 alkyl substituted with 0-3 R^{1a},
C_2-C_6 alkenyl substituted with 0-3 R^{1a},
C_2-C_6 alkynyl substituted with 0-3 R^{1a}, and

C_3-C_6 cycloalkyl substituted with 0-3 R^{1a};

R^{1a} is selected at each occurrence from the group:
Cl, F, Br, I, CF_3, CHF_2, OH, =O, SH, $-CO_2R^{1b}$, $-SO_2R^{1b}$, $-SO_3R^{1b}$, $-P(O)_2R^{1b}$, $-P(O)_3R^{1b}$, $-C(=O)NHR^{1b}$, $-NHC(=O)R^{1b}$, $-SO_2NHR^{1b}$, $-OR^{1b}$, $-SR^{1b}$, C_1-C_3 alkyl, C_3-C_6 cycloalkyl, C_1-C_6 alkoxy, $-S-(C_1$-C_6 alkyl),
aryl substituted with 0-5 R^{1c},
$-O-(CH_2)_q$-aryl substituted with 0-5 R^{1c},
$-S-(CH_2)_q$-aryl substituted with 0-5 R^{1c}, and
5-10 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N, and substituted with 0-3 R^{1c};

R^{1b} is H,
C_1-C_4 alkyl substituted with 0-3 R^{1c},
C_2-C_4 alkenyl substituted with 0-3 R^{1c},
C_2-C_4 alkynyl substituted with 0-3 R^{1c},
C_3-C_6 cycloalkyl substituted with 0-5 R^{1c},
C_3-C_6 carbocyle substituted with 0-5 R^{1c},
aryl substituted with 0-5 R^{1c}, or
5-6 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N, said heterocyclic group substituted with 0-4 R^{1c};

R^{1c} is selected at each occurrence from: C_1-C_4 alkyl, Cl, F, Br, I, OH, C_1-C_4 alkoxy, -CN, $-NO_2$, $C(O)OR^{1d}$, $NR^{1d}R^{1d}$, CF_3, and OCF_3;

R^{1d} is H or C_1-C_4 alkyl;

R^2 is H or C_1-C_4 alkyl;

R^3 is selected from the group: H,
C_1-C_6 alkyl substituted with 0-4 R^{3a},
C_2-C_6 alkenyl substituted with 0-4 R^{3a},
C_2-C_6 alkynyl substituted with 0-4 R^{3a},
$-(CH_2)_q$- C_3-C_6 cycloalkyl substituted with 0-4 R^{3b},
$-(CH_2)_q$-aryl substituted with 0-5 R^{3b}, and
$-(CH_2)_q$-5-10 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N, and said heterocyclic group is substituted with 0-2 R^{3b};

R^{3a} is selected from the group: $-CO_2R^{11}$, $-NR^{11}R^{11}$, $-OR^{11}$, $-SR^{11}$, $-C(=NH)NH_2$, and aryl substituted with R^{10b};

R^{3b} is selected from the group: $-CO_2H$, $-NH_2$, $-OH$, $-SH$, and $-C(=NH)NH_2$;

R^{3c} is, at each occurrence, independently selected from: H, C_1-C_6 alkyl, $-OH$, and OR^{3d};

R^{3d} is C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, $-(CH_2)_q$- C_3-C_6 cycloalkyl, $-(CH_2)_q$-aryl, or $-(CH_2)_q$-(5-10 membered heterocyclic group), wherein said heterocyclic group consists of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N;

R^4 is selected from the group: H, C_1-C_6 alkyl, phenyl, phenylmethyl-, phenylethyl-, C_3-C_6 cycloalkyl, C_3-C_6 cycloalkylmethyl-, and C_3-C_6 cycloalkylethyl-;

R^9 is selected from the group: $-S(=O)_2R^{9a}$, $-C(=O)R^{9a}$, C_1-C_3 alkyl-R^{9a}, C_2-C_6 alkenyl-R^{9a}, and C_2-C_6 alkynyl-R^{9a};

R^{9a} is selected from the group:
C_1-C_6 alkyl substituted with 0-3 R^{9b},
C_3-C_6 cycloalkyl substituted with 0-3 R^{9c},
aryl substituted with 0-3 R^{9c}, and
5-14 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N, and said heterocyclic group is substituted with 0-3 R^{9c};

R^{9b} is selected from the group: phenyl, naphthyl, benzyl, and 5-10 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N, and R^{9b} is substituted with 0-3 R^{9c};

R^{9c} is selected at each occurrence from the group:
CF_3, OCF_3, Cl, F, Br, I, =O, OH, phenyl, $C(O)OR^{11}$, NH_2, $NH(CH_3)$, $N(CH_3)_2$, -CN, NO_2;
C_1-C_4 alkyl substituted with 0-3 R^{9d},
C_1-C_4 alkoxy substituted with 0-3 R^{9d},
C_3-C_6 cycloalkyl substituted with 0-3 R^{9d},
aryl substituted with 0-5 R^{9d}, and
5-6 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N, and said heterocyclic group is substituted with 0-4 R^{9d};

R^{9d} is selected at each occurrence from the group:
C_1-C_4 alkyl, C_1-C_4 alkoxy, CF_3, OCF_3, Cl, F, Br, I, =O, OH, phenyl, $C(O)OR^{11}$, NH_2, $NH(CH_3)$, $N(CH_3)_2$, -CN, and NO_2;

n is 1 or 2; and

p is 1 or 2; and

q, at each occurence, is independently 0, 1 or 2.

11. A compound according to Claim 4, wherein the compound is of Formula (IIIb):



(IIIb)

or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein;

Q^1 is selected from
$-CO_2R^{11}$, $-SO_2R^{11}$, $-SO_3R^{11}$, $-P(O)_2R^{11}$, $-P(O)_3R^{11}$,
aryl substituted with 0-4 Q^{1a}, and
5-6 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: pyridinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, pyrazinyl, piperazinyl, piperidinyl, imidazolyl, imidazolidinyl, indolyl, tetrazolyl, isoxazolyl, morpholinyl, oxazolyl, oxazolidinyl, tetrahydrofuranyl, thiadiazinyl, thiadiazolyl, thiazolyl, triazinyl, and triazolyl; said heterocyclic group substituted with 0-4 Q^{1a};

Q^{1a} is H, F, Cl, Br, I, $-NO_2$, -CN, -NCS, $-CF_3$, $-OCF_3$, $-CH_3$, $-OCH_3$, $-CO_2R^{19}$, $-C(=O)NR^{19}R^{19}$, $-NHC(=O)R^{19}$, $-SO_2R^{19}$, $-SO_2NR^{19}R^{19}$, $-NR^{19}R^{19}$, $-OR^{19}$, $-SR^{19}$, C_1-C_4 alkyl, C_1-C_4 alkoxy, C_1-C_4 haloalkyl, or C_1-C_4 haloalkoxy;

R^{19} is C_1-C_4 alkyl, C_1-C_4 haloalkyl, aryl, aryl(C_1-C_4 alkyl), C_3-C_6 cycloalkyl, or C_3-C_6 cycloalkyl(C_1-C_4 alkyl);

alternatively, $NR^{19}R^{19}$ may form a piperidinyl, piperazinyl, or morpholinyl group;

A^2 is a bond, $-NH-CR^3R^4-C(=O)-$, Ala, Arg, Asn, Asp, Aze, Cha, Cys, Dpa, Gln, Glu, Gly, His, Hyp, Ile, Irg, Leu, Lys, Met, Orn, Phe, Phe(4-fluoro), Pro, Sar, Ser, Thr, Trp, Tyr, Val,




or ;

A^3 is a bond, Ala, Arg, Asn, Asp, Aze, Cha, Cys, Dpa, Gln, Glu, Gly, His, Hyp, Ile, Irg, Leu, Lys, Met, Orn, Phe, Phe(4-fluoro), Pro, Sar, Ser, Thr, Trp, Tyr, or Val;

A^4 is a bond, Ala, Arg, Asn, Asp, Aze, Cha, Cys, Dpa, Gln, Glu, Gly, His, Hyp, Ile, Irg, Leu, Lys, Met, Orn, Phe, Phe(4-fluoro), Pro, Sar, Ser, Thr, Trp, Tyr, or Val;

R^1 is selected from the group: H,
C_1-C_6 alkyl substituted with 0-3 R^{1a},
C_2-C_6 alkenyl substituted with 0-3 R^{1a},
C_2-C_6 alkynyl substituted with 0-3 R^{1a}, and
C_3-C_6 cycloalkyl substituted with 0-3 R^{1a};

R^{1a} is selected at each occurrence from the group:
Cl, F, Br, I, CF_3, CHF_2, OH, =O, SH, $-CO_2R^{1b}$, $-SO_2R^{1b}$, $-SO_3R^{1b}$, $-P(O)_2R^{1b}$, $-P(O)_3R^{1b}$, $-C(=O)NHR^{1b}$, $-NHC(=O)R^{1b}$, $-SO_2NHR^{1b}$, $-OR^{1b}$, $-SR^{1b}$, C_1-C_3 alkyl, C_3-C_6 cycloalkyl, C_1-C_6 alkoxy, -S-(C_1-C_6 alkyl),
aryl substituted with 0-5 R^{1c},
$-O-(CH_2)_q$-aryl substituted with 0-5 R^{1c},
$-S-(CH_2)_q$-aryl substituted with 0-5 R^{1c}, and
5-10 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: pyridinyl, furanyl, thienyl, pyrrolyl, pyrazolyl,

pyrazinyl, piperazinyl, piperidinyl, imidazolyl, imidazolidinyl, indolyl, tetrazolyl, isoxazolyl, morpholinyl, oxazolyl, oxazolidinyl, tetrahydrofuranyl, thiadiazinyl, thiadiazolyl, thiazolyl, triazinyl, triazolyl, benzimidazolyl, 1*H*-indazolyl, benzofuranyl, benzothiofuranyl, benztetrazolyl, benzotriazolyl, benzisoxazolyl, benzoxazolyl, oxindolyl, benzoxazolinyl, benzthiazolyl, benzisothiazolyl, isatinoyl, isoquinolinyl, octahydroisoquinolinyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, isoxazolopyridinyl, quinazolinyl, quinolinyl, isothiazolopyridinyl, thiazolopyridinyl, oxazolopyridinyl, imidazolopyridinyl, and pyrazolopyridinyl; and substituted with 0-3 R^{1c};

R^{1b} is H,

C_1-C_4 alkyl substituted with 0-3 R^{1c},

C_2-C_4 alkenyl substituted with 0-3 R^{1c},

C_2-C_4 alkynyl substituted with 0-3 R^{1c},

C_3-C_6 cycloalkyl substituted with 0-5 R^{1c},

C_3-C_6 carbocyle substituted with 0-5 R^{1c},

aryl substituted with 0-5 R^{1c}, or

5-6 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: pyridinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, pyrazinyl, piperazinyl, piperidinyl, imidazolyl, imidazolidinyl, indolyl, tetrazolyl, isoxazolyl, morpholinyl, oxazolyl, oxazolidinyl, tetrahydrofuranyl, thiadiazinyl, thiadiazolyl, thiazolyl, triazinyl, and triazolyl; said heterocyclic group substituted with 0-4 R^{1c};

R^{1c} is selected at each occurrence from: C_1-C_4 alkyl, Cl, F, Br, I, OH, C_1-C_4 alkoxy, -CN, -NO_2, $C(O)OR^{1d}$, $NR^{1d}R^{1d}$, CF_3, and OCF_3;

R^{1d} is H or C_1-C_4 alkyl;

R^2 is H or C_1-C_4 alkyl;

R^3 is selected from the group: H,
C_1-C_6 alkyl substituted with 0-4 R^{3a},
C_2-C_6 alkenyl substituted with 0-4 R^{3a},
C_2-C_6 alkynyl substituted with 0-4 R^{3a},
$-(CH_2)_q$- C_3-C_6 cycloalkyl substituted with 0-4 R^{3b},
$-(CH_2)_q$-aryl substituted with 0-5 R^{3b}, and
$-(CH_2)_q$-5-10 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: pyridinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, pyrazinyl, piperazinyl, piperidinyl, imidazolyl, imidazolidinyl, indolyl, tetrazolyl, isoxazolyl, morpholinyl, oxazolyl, oxazolidinyl, tetrahydrofuranyl, thiadiazinyl, thiadiazolyl, thiazolyl, triazinyl, triazolyl, benzimidazolyl, 1*H*-indazolyl, benzofuranyl, benzothiofuranyl, benztetrazolyl, benzotriazolyl, benzisoxazolyl, benzoxazolyl, oxindolyl, benzoxazolinyl, benzthiazolyl, benzisothiazolyl, isatinoyl, isoquinolinyl, octahydroisoquinolinyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, isoxazolopyridinyl, quinazolinyl, quinolinyl, isothiazolopyridinyl, thiazolopyridinyl, oxazolopyridinyl, imidazolopyridinyl, and pyrazolopyridinyl; and said heterocyclic group is substituted with 0-2 R^{3b};

R^{3a} is selected from the group: $-CO_2R^{11}$, $-NR^{11}R^{11}$, $-OR^{11}$, $-SR^{11}$, $-C(=NH)NH_2$, and aryl substituted with R^{10b};

R^{3b} is selected from the group: $-CO_2H$, $-NH_2$, -OH, -SH, and $-C(=NH)NH_2$;

R^{3c} is, at each occurrence, independently selected from: H, C_1-C_6 alkyl, -OH, and OR^{3d};

R^{3d} is C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, $-(CH_2)_q$- C_3-C_6 cycloalkyl, $-(CH_2)_q$-aryl, or $-(CH_2)_q$-(5-10 membered heterocyclic group), wherein said heterocyclic group consists of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N;

R^4 is selected from the group: H, C_1-C_6 alkyl, phenyl, phenylmethyl-, phenylethyl-, C_3-C_6 cycloalkyl, C_3-C_6 cycloalkylmethyl-, and C_3-C_6 cycloalkylethyl-;

R^9 is selected from $-S(=O)_2R^{9a}$ and $-C(=O)R^{9a}$;

R^{9a} is selected from the group:
phenyl substituted with 0-3 R^{9c},
naphthyl substituted with 0-3 R^{9c}, and
5-14 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: pyridinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, pyrazinyl, piperazinyl, piperidinyl, imidazolyl, imidazolidinyl, indolyl, tetrazolyl, isoxazolyl, morpholinyl, oxazolyl, oxazolidinyl, tetrahydrofuranyl, thiadiazinyl, thiadiazolyl, thiazolyl, triazinyl, triazolyl, benzimidazolyl, 1*H*-indazolyl, benzofuranyl, benzothiofuranyl, benztetrazolyl, benzotriazolyl, benzisoxazolyl, benzoxazolyl, oxindolyl, benzoxazolinyl, benzthiazolyl, benzisothiazolyl, isatinoyl, isoquinolinyl, octahydroisoquinolinyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, isoxazolopyridinyl, quinazolinyl, quinolinyl, isothiazolopyridinyl, thiazolopyridinyl,

oxazolopyridinyl, imidazolopyridinyl, and pyrazolopyridinyl; and said heterocyclic group is substituted with 0-3 R^{9c};

R^{9c} is selected at each occurrence from the group:

CF_3, OCF_3, Cl, F, Br, I, =O, OH, phenyl, $C(O)OR^{11}$, NH_2, $NH(CH_3)$, $N(CH_3)_2$, -CN, NO_2;

C_1-C_4 alkyl substituted with 0-3 R^{9d},

C_1-C_4 alkoxy substituted with 0-3 R^{9d},

C_3-C_6 cycloalkyl substituted with 0-3 R^{9d},

aryl substituted with 0-5 R^{9d}, and

5-6 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: pyridinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, pyrazinyl, piperazinyl, piperidinyl, imidazolyl, imidazolidinyl, indolyl, tetrazolyl, isoxazolyl, morpholinyl, oxazolyl, oxazolidinyl, tetrahydrofuranyl, thiadiazinyl, thiadiazolyl, thiazolyl, triazinyl, and triazolyl; and said heterocyclic group is substituted with 0-4 R^{9d};

R^{9d} is selected at each occurrence from the group:

C_1-C_4 alkyl, C_1-C_4 alkoxy, CF_3, OCF_3, Cl, F, Br, I, =O, OH, phenyl, $C(O)OR^{11}$, NH_2, $NH(CH_3)$, $N(CH_3)_2$, -CN, and NO_2;

p is 1 or 2; and

q, at each occurence, is independently 0, 1 or 2.

12. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt form thereof.

13. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 2 or a pharmaceutically acceptable salt form thereof.

14. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 3 or a pharmaceutically acceptable salt form thereof.

15. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 4 or a pharmaceutically acceptable salt form thereof.

16. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 5 or a pharmaceutically acceptable salt form thereof.

17. A method of treating a viral infection which comprises administering to a host in need of such treatment a therapeutically effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt form thereof.

18. A method of treating HCV infection which comprises administering to a host in need of such treatment a therapeutically effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt form thereof.

19. A compound of Claim 1 or a pharmaceutically acceptable salt form thereof for use in therapy.

20. Use of a compound of Claim 1 or a pharmaceutically acceptable salt form thereof for the manufacture of a medicament for the treatment of HCV.